Adenosine receptors in vascular sympathetic neurotransmission: The role of endothelium and of nitric oxide-mediated effects and their relation with hypertension by Joana Beatriz Alves da Silva Pinheiro de Sousa
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
ADENOSINE RECEPTORS IN VASCULAR SYMPATHETIC 
NEUROTRANSMISSION: THE ROLE OF ENDOTHELIUM AND OF 
NITRIC OXIDE-MEDIATED EFFECTS AND THEIR RELATION 
WITH HYPERTENSION 
 
 
 
JOANA BEATRIZ ALVES DA SILVA PINHEIRO DE SOUSA 
 
 
 
 
TESE DO 3º CICLO DE ESTUDOS CONDUCENTE AO GRAU DE DOUTORAMENTO EM 
CIÊNCIAS FARMACÊUTICAS NA ESPECIALIDADE DE FARMACOLOGIA E 
FARMACOTERAPIA 
 
 
 
 
 
Trabalho realizado sob a orientação da Professora Doutora Carmen Diniz 
Pereira, Professora Auxiliar da Faculdade de Farmácia da Universidade do 
Porto e co-orientação da Professora Doutora Paula Maria Façanha da Cruz 
Fresco, Professora Associada da Faculdade de Farmácia da Universidade do 
Porto. 
 
 
JULHO de 2014  
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A 
REPRODUÇÃO DE QUALQUER PARTE DESTA TESE 
  
 iii 
 
DECLARAÇÃO 
 
Ao abrigo do nº2 do artigo 8º do Decreto-Lei nº388/70, declara-se que fazem parte 
integrante desta tese os seguintes trabalhos publicados ou submetidos. Para esses 
trabalhos, o autor da tese contribuiu maioritariamente na execução das experiências 
laboratoriais, interpretação de resultados e preparação dos manuscritos. 
 
PUBLICAÇÕES ACEITES OU SUBMETIDAS DURANTE O DOUTORAMENTO 
 
Capítulos de livros 
 
Leitão-Rocha A, Sousa JB and Diniz C. Adenosinergic System in the Mesenteric Vessels. In 
book: The Cardiovascular System - Physiology, Diagnostics and Clinical Implications, 2012. 
David Gaze (Ed.). Source: InTech 
 
Sousa JB, Fresco P and Diniz C. Imaging receptors with Laser Scanning Confocal 
Microscopy: qualitative and quantitative analysis. Microscopy: advances in scientific 
research and education, 2014. A. Méndez-Vilas (Ed.)  
 
Artigos Científicos  
 
Rocha-Pereira C, Sousa JB, Vieira-Rocha MS, Fresco P, Gonçalves J, Diniz C. “Differential 
inhibition of noradrenaline release mediated by inhibitory A₁-adenosine receptors in the 
mesenteric vein and artery from normotensive and hypertensive rats.” Neurochemistry 
International. 62, 399-405 (2013).  
 
Sousa JB, Fresco P, Diniz C. “Endothelial nitric oxide modulatory role on vascular 
sympathetic reactivity.” Published in Medimond International Proceedings, 43-47 (2013).  
 
Sousa JB, Vieira-Rocha MS, Sá C, Ferreirinha F, Correia-de-Sá P, Fresco P, Diniz C. Lack of 
endogenous adenosine tonus on sympathetic neurotransmission in spontaneously 
hypertensive rat mesenteric artery. Accepted for publication on PLoS One, 2014. 
 
Sousa JB, Fresco P, Diniz C. Endothelial dysfunction impairs vascular neurotransmission 
in tail arteries. Submitted to Neurochemistry International. 
 
Sousa JB, Vieira-Rocha MS, Arribas SM, González MC, Fresco P, Diniz C. Nitric oxide 
production in mesenteric and tail arteries: differential role of eNOS and nNOS in 
sympathetic neurotransmission. Submitted to Nitric Oxide: Biology and Chemistry.

 v 
 
AGRADECIMENTOS 
 
“A coisa mais bela que o homem pode experimentar é o mistério. 
 É essa emoção fundamental que está na raiz de toda ciência e toda arte.” 
 
Albert Einstein 
 
 
 
Uma Tese de Doutoramento é uma longa viagem, com muitas tribulações pelo caminho.  
Ao concluir esta tese de doutoramento, quero deixar meu o reconhecimento a pessoas e 
instituições pelo auxílio que me prestaram e que, de forma decisiva, contribuíram para a 
sua realização. 
 
Começo por agradecer à Professora Doutora Carmen Diniz pelo seu entusiasmo, apoio, 
tolerância, disponibilidade, motivação e espirito crítico na orientação desta tese, mas 
sobretudo pelos alicerces de tudo isto…a amizade que foi crescendo ao longo destes 8 anos 
em que já trabalhamos juntas. 
 
À Professora Doutora Paula Fresco pelo incentivo e apreciação científica dos resultados 
experimentais e pelo seu apoio sempre que precisei mas sobretudo pela sua amizade e 
carinho. 
 
Ao Professor Paulo Correia de Sá por disponibilizar o microscópio confocal para a 
visualização e aquisição de imagens das artérias em estudo e pelo apoio científico na 
elaboração do manuscrito resultante da colaboração que estabelecemos. 
 
À Doutora Fátima Ferreirinha pela imensa paciência e disponibilidade na “aventura de 
explorar” uma nova área para ambas, no “universo da microscopia confocal”. A dificuldade 
inicial foi ultrapassada graças às suas sugestões, boa vontade e amizade que se criou nas 
“intermináveis sessões” que jamais esquecerei. 
 
À Professora Silvia Arribas e Maria Carmen González do Departamento de Fisiologia, da 
Faculdade de Medicina, da Universidade Autónoma de Madrid, pela possibilidade de 
realizar parte do trabalho desta tese no seu laboratório, pela simpatia e boa vontade com 
que me receberam e acompanharam o trabalho lá realizado. 
 
Ao Professor Carlos Sá do Centro de Materiais da Universidade do Porto pela elaboração 
das macros desenvolvidas especificamente para o trabalho de quantificação das imagens de 
confocal desta tese. 
 
vi 
 
À Céu e à Mónica pela amizade, ensinamentos e ajuda sempre que precisei no decorrer do 
trabalho experimental desta tese, não esquecendo os bons momentos “extra-trabalho” que 
partilhamos. 
 
À Ana, à Diana e à Sofia pela amizade, entreajuda e partilha dos bons e maus momentos do 
nosso dia-a-dia, e pelos momentos de descontração, tão importantes nesta vida de 
investigação. 
 
A todos os membros do Serviço de Farmacologia da Faculdade de Farmácia da Universidade 
do Porto pelo bom ambiente, simpatia e sentido de entreajuda que juntos criamos. 
 
 
Passo agora a agradecer às pessoas mais importantes da minha vida, e que me ajudam a 
crescer como ser humano. 
 
À minha tão amada família, de modo especial à minha mãe, ao meu pai e aos meus irmãos, 
por todo o carinho, apoio e ensinamentos em todos os momentos da minha vida, com eles 
ao meu lado, tudo é mais fácil! 
 
E, por fim, todas as palavras são poucas para agradecer ao Pedro pelo seu amor, incentivo 
diário e apoio incondicional, por tornar os meus dias mais leves e pela capacidade de 
transformar uma lágrima num sorriso…. 
 
 
 
 
 
 
 
 
 
 
 
  
 vii 
 
A candidata desenvolveu o seu trabalho experimental com o apoio de uma bolsa de 
Doutoramento (SFRH/BD/64911/2009) financiada pela Fundação para a Ciência e 
Tecnologia (FCT) que também apoiou os estudos desenvolvidos em Madrid.  
Este trabalho foi, também, financiado pelo Fundo Europeu de Desenvolvimento Regional 
(FEDER) através do Programa Operacional de Factores de Competitividade (COMPETE) 
sem os quais a realização desta tese não teria sido possível. 
 
O Laboratório de Farmacologia do Departamento de Ciências do Medicamento da 
Faculdade de Farmácia da Universidade do Porto e o laboratório associado REQUIMTE 
providenciaram as instalações e apoio logístico necessário ao trabalho desenvolvido. 
 
 
 
 
 
 
 
 
 
 

 ix 
 
ABSTRACT  
 
Increased sympathetic activity has been implicated in hypertension. Adenosine 
provides a link between local mechanisms of blood flow autoregulation and systemic 
mechanisms of autonomic cardiovascular regulation. Endothelial cells interact with 
adenosine mechanisms in many different ways. Endothelium is widely recognized as an 
important regulator of blood vessel tone via release of various endothelium-derived 
endogenous substances, such as nitric oxide.  Endothelial cells are known to have a very 
active adenosine metabolism, characterized by a large capacity for uptake and release of this 
nucleoside. Adenosine may modulate endothelial function via activation of cell membrane 
receptors. The precise nature of the interaction between adenosine receptor subtypes and 
endothelial cells and their role in the regulation of endothelial function is not completely 
understood. However, adenosine-induced production of nitric oxide by endothelial cells is 
recognized.  
The present study intends to clarify the neuromodulatory role exerted by 
endogenous adenosine and nitric oxide (generated by endothelial and neuronal nitric oxide 
synthases) in sympathetic neurotransmission, to evaluate if endothelium dysfunction 
impairs vascular sympathetic neurotransmission and to explore the distribution profiles of 
adenosine A1 and A2A receptors and of neuronal nitric oxide synthase isoform in the 
adventitia layer of mesenteric and tail arteries of both normotensive and hypertensive rats. 
Electrically-evoked tritium overflow (100 pulses/5 Hz) was evaluated on Wistar 
Kyoto and spontaneously hypertensive rats mesenteric and tail arteries, pre-incubated with 
[3H]-noradrenaline. The role of endogenous adenosine and nitric oxide in sympathetic 
neurotransmission was studied in the presence of adenosine receptor agonists and 
antagonists; enzymes substrates and inhibitors; nitric oxide donors and a nucleoside 
transporter inhibitor. Purine content was determined by HPLC with fluorescence detection. 
The distribution profiles of adenosine A1 and A2A receptors and of neuronal nitric oxide 
synthase isoform in the adventitia layer of mesenteric and tail arteries of Wistar Kyoto and 
Spontaneously Hypertensive rats was investigated by Laser Scanning Confocal Microscopy. 
Results indicate a higher electrically-evoked noradrenaline release from 
hypertensive mesenteric and tail arteries comparatively to those from normotensive vessels. 
In intact Wistar Kyoto arteries, a facilitation of tritium overflow was observed in the 
presence of an selective adenosine A1 receptor antagonist. This effect can be ascribed to a 
tonic inhibitory effect mediated by A1 receptors. In denuded and hypertensive arteries, in 
the presence of an adenosine A2A receptor antagonist a reduction of tritium overflow was 
observed. Moreover, when endogenous adenosine bioavailability was increased by the 
nucleoside transporter inhibitor, tritium overflow increased in intact, denuded and 
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hypertensive arteries, suggesting the occurrence of a tonic activation of A2A receptors. The 
tonic inhibitory modulation of noradrenaline release is mediated by A1 adenosine receptors 
and is lacking in arteries from hypertensive animals, despite their purine content being 
higher comparatively to normotensive ones.  
Nitric oxide donors reduced noradrenaline release in mesenteric arteries while, in 
tail arteries, caused the opposite effect. In mesenteric arteries, both a neuronal nitric oxide 
synthase inhibitor and an endothelial nitric oxide synthase inhibitor, increased 
noradrenaline release. However, in intact tail arteries, inhibition of endothelial nitric oxide 
synthase lead to a reduction of noradrenaline release whereas inhibition of neuronal nitric 
oxide synthase was devoid of effect showing that only endothelial nitric oxide synthase is 
involved in vascular sympathetic neuromodulation. Nitric oxide modulatory role on 
sympathetic neurotransmission differs in the mesenteric and tail arteries depending on the 
nitric oxide synthase isoform, endothelial nitric oxide synthase and/or neuronal nitric oxide 
synthase, involved in its production. 
Immunohistochemistry revealed an adenosine A1 receptors redistribution from 
sympathetic fibers to Schwann cells, in hypertensive mesenteric arteries adventitia which 
can explain, at least in part, the absence of effect of these receptors in hypertensive arteries.  
Moreover, immunohistochemical studies also revealed neuronal nitric oxide synthase 
locatization presence in Schwann cells which seem to be the main source of nitric oxide to 
perivascular sympathetic nerves. Moreover, lower amounts of neuronal nitric oxide 
synthase were found in tail arteries comparatively to those observed in mesenteric arteries.  
In the experimental conditions of this work, the inhibition of enzymes involved in 
reactive oxygen species or prostaglandins production (with apocynin and allopurinol or 
indomethacin, respectively) failed to alter tritium overflow. 
Data highlight the role of purines in hypertension by revealing that an increase in 
sympathetic activity in hypertensive arteries is occurring due to a higher noradrenaline and 
ATP release from sympathetic nerves and the loss of endogenous adenosine inhibitory 
tonus. The observed nerve-to-glial redistribution of inhibitory A1 adenosine receptors in 
hypertensive arteries may explain the latter effect. Furthermore, among the endothelium-
derived factors studied that could alter vascular sympathetic transmission, adenosine and 
adenosine receptor mediated mechanisms were clearly impaired by endothelium 
injury/dysfunction.  
 
Keywords: mesenteric artery, tail artery, adenosine, nitric oxide, noradrenaline, 
hypertension.  
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RESUMO  
 
O aumento da atividade simpática tem sido implicado na hipertensão. A adenosina 
fornece uma ligação entre os mecanismos locais de autoregulação do fluxo sanguíneo e 
mecanismos sistémicos de regulação cardiovascular do sistema nervoso autónomo. O 
endotélio é um componente vascular amplamente reconhecido como sendo um importante 
regulador do tónus vascular através da libertação de diversas substâncias endógenas, como 
por exemplo o monóxido de azoto. As células endoteliais são reconhecidas como tendo um 
metabolismo de adenosina muito ativo, caracterizado por uma grande capacidade de 
captação e libertação do nucleosídeo. A adenosina pode, ainda, modular a função endotelial 
por meio da ativação de recetores de membrana. O tipo de interação entre os subtipos de 
recetores de adenosina e as células endoteliais bem como o seu papel na regulação da função 
endotelial está longe de estar esclarecido. No entanto, a produção de monóxido de azoto 
pelas células endoteliais induzida pela adenosina é amplamente reconhecida. 
Com o presente estudo pretendeu-se esclarecer o papel neuromodulador exercido 
pela adenosina endógena e pelo monóxido de azoto na neurotransmissão simpática, avaliar 
se a disfunção endotelial afeta a neurotransmissão simpática vascular e explorar o perfil de 
distribuição dos recetores da adenosina A1 e A2A e da sintase neuronal do monóxido azoto 
na camada adventícia de artérias mesentéricas e artérias da cauda de ratos normo e 
hipertensos. 
No trabalho experimental deste trabalho, realizaram-se ensaios de libertação de 
trítio por estimulação elétrica (100 pulses/5 Hz) com a artéria mesentérica e artéria da 
cauda de ratos Wistar Kyoto e de ratos espontaneamente hipertensos, pré-incubadas com 
[3H]-noradrenalina. O papel da adenosina endógena e do monóxido de azoto na 
neurotransmissão simpática foi estudada na presença de agonistas e antagonistas de 
recetores; substratos e inibidores de enzimas; dadores de monóxido de azoto e um inibidor 
dos transportadores de adenosina. O teor de purinas libertado foi, ainda, determinado por 
HPLC com deteção por fluorescência. 
O perfil de distribuição dos recetores de adenosina A1 e A2A e da sintase neuronal do 
monóxido de azoto, na camada adventícia da artéria mesentérica e da artéria da cauda de 
ratos Wistar Kyoto e espontaneamente hipertensos foi investigado por microscopia 
confocal. 
Os resultados revelaram ocorrer uma maior libertação de noradrenalina por 
estimulação elétrica na artéria mesentérica e na artéria da cauda de ratos hipertensos 
comparativamente com os normotensos. Em artérias intactas de ratos normotensos, foi 
observado um aumento da libertação de trítio na presença do antagonista dos recetores de 
adenosina A1. Este efeito pode ser atribuído a um efeito tónico inibitório mediado pelos 
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recetores A1. Na presença do antagonista dos recetores de adenosina A2A, em artérias onde 
o endotélio foi removido e nas artérias de ratos hipertensos, foi observada uma redução na 
libertação de trítio. Adicionalmente, quando a biodisponibilidade de adenosina endógena 
foi aumentada pelo inibidor dos transportadores de adenosina, verificou-se um aumento da 
libertação de trítio em artérias intactas, em artérias sem endotélio e em artérias de ratos 
hipertensos, sugerindo a ocorrência de uma ativação tónica dos recetores de adenosina A2A. 
A modulação inibitória tónica de libertação de noradrenalina é mediado pelos recetores de 
adenosina A1 que parece estar ausente em artérias de animais hipertensos, apesar do seu 
teor em purinas ser maior comparativamente ao dos normotensos.  
Por outro lado, os dadores de monóxido de azoto promoveram uma redução na 
libertação de noradrenalina na artéria mesentérica, enquanto na artéria da cauda, causaram 
o efeito oposto. Na artéria mesentérica, tanto o inibidor específico da enzima sintase 
neuronal do monóxido de azoto como o inibidor específico da sintase endotelial do 
monóxido de azoto, promoveram um aumento da libertação de noradrenalina. No entanto, 
na artéria da cauda intacta, a inibição da sintase endotelial do monóxido de azoto reduziu a 
libertação de noradrenalina enquanto a inibição da sintase neuronal do monóxido de azoto 
não teve qualquer efeito, mostrando que apenas a sintase endotelial do monóxido de azoto 
está envolvida na neuromodulação simpática da artéria da cauda. Assim sendo, o papel 
modulador do monóxido de azoto na neurotransmissão simpática difere nas duas artérias 
em estudo e depende da isoforma da sintase do monóxido de azoto, endotelial ou neuronal, 
envolvida na sua produção. 
Estudos imunohistoquímicos revelaram uma redistribuição dos recetores A1 de 
adenosina das fibras simpáticas para as células de Schwann, na camada adventícia de 
artérias mesentéricas de ratos hipertensos, o que pode explicar, pelo menos em parte, a falta 
de efeito destes recetores nestas artérias. Para além disso, os estudos imunohistoquímicos 
revelaram a presença da sintase neuronal do monóxido de azoto em células de Schwann 
parecendo ser esta enzima a fonte principal de monóxido de azoto em nervos simpáticos 
perivasculares. Além disso, verificou-se uma menor quantidade de sintase neuronal do 
monóxido de azoto na artéria da cauda, comparativamente com a observada na artéria 
mesentérica.  
Nas condições experimentais deste estudo, a inibição das enzimas envolvidas na 
produção de espécies reativas de oxigénio ou de prostaglandinas (com apocinina e 
alopurinol ou indometacina, respetivamente) não conseguiu alterar a libertação de 
noradrenalina.  
Os resultados deste trabalho destacam o papel das purinas na hipertensão, 
revelando que um aumento na atividade simpática em artérias de ratos hipertensos ocorre 
devido a uma maior libertação de noradrenalina e ATP de nervos simpáticos e a perda do 
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tónus inibitório da adenosina endógena. A redistribuição nervo-glial observada dos 
recetores de adenosina A1 inibitórios em artérias de ratos hipertensos pode explicar este 
aumento da libertação de noradrenalina e ATP observado. Para além disso, entre as 
substâncias/fatores derivados do endotélio estudados, que poderiam alterar a transmissão 
simpática vascular, a adenosina e os mecanismos mediados por este nucleósido estão 
claramente comprometidos pela disfunção ou lesão endotelial.  
 
 
Palavras-chave: artéria mesentérica, artéria da cauda, adenosina, monóxido de azoto, 
noradrenalina, hipertensão. 
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1. INTRODUCTION 
 
1.1 Vessels 
 
Blood vessels are an intricate part of the circulatory system, and are the structures 
through which blood flows throughout the body. Blood vessels are involved in every 
pathological condition, including cancer, inflammation and cardiovascular disease. There 
are several types of vessels, each designed for a special purpose in various parts of the body. 
Arteries and veins vary largely in the thickness of their walls, the diameters of their lumen 
or their elasticity.  
Arteries and veins have a similar structure (Figure 1). Surrounding the lumen is the 
innermost layer, the tunica intima, which is the thinnest layer, made up of simple 
endothelial cells and lines the entire circulatory system. Also included in this thin layer are 
circular, elastic bands, the internal elastic lamina. The second layer, the tunica media, is 
made up of more circular elastic bands, the external elastic lamina. The tunica media 
contains vascular smooth muscle which helps regulate the size of the lumen and those of 
arteries contains more smooth muscle than the tunica media of their counterpart, the veins, 
and this allows arteries to constrict and dilate to adjust the volume of blood needed by the 
tissues that they support.  
 
 
 
 
Figure 1 – Schematic representation of vessels wall. (adapted from Copyright McGraw-Hill 
Companies, Inc) 
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When the smooth muscle found within the tunica media is stimulated, it contracts, 
squeezing the walls of the artery and narrowing the lumen vessel. The term vasoconstriction 
is used to describe the narrowing of the blood vessel due to contraction of the muscular wall. 
When an artery constricts, the blood flow decreases and the pressure within the vessel rises. 
Vasoconstriction is a mechanism that body uses to regulate important functions, such as 
body temperature and blood pressure. Vasodilation is the opposite of vasoconstriction and 
consists in the widening of the blood vessel due to relaxation of the muscular wall. When a 
blood vessel dilates, blood is able to flow through the vessel with less resistance. Therefore, 
vasodilation has the opposite effect of vasoconstriction on such functions as body 
temperature and blood pressure. The tunica adventitia is the outermost layer of the arteries 
and veins. This outer layer is composed of connective tissue that allows the blood vessel to 
withstand forces acting on the vessel wall. It also contains strong collagen fibers that help 
anchor the blood vessel to surrounding tissues, and this gives the vessel some stability.  
Over the last years, endothelium has emerged as a key regulator of vascular 
homeostasis, and is no longer looked as having only a barrier function but also as an active 
signal transducer for circulating influences that modify the vessel wall phenotype. 
Alteration in endothelial function precedes the development of morphological 
atherosclerotic changes and can also contribute to lesion development and later clinical 
complications.[1] 
Endothelium is able to respond to physical and chemical signals by production of a 
wide range of factors that regulate vascular tone, cellular adhesion, thromboresistance, 
smooth muscle cell proliferation, and vessel wall inflammation. Endothelium effect on 
vascular tone is achieved by production and release of several vasoactive molecules that 
relax or constrict the vessel, as well as by response to and modification of circulating 
vasoactive mediators. This vasomotion plays a direct role in the balance of tissue oxygen 
supply and metabolic demand by regulation of vessel tone and diameter, and is also involved 
in the remodeling of vascular structure and long-term organ perfusion.[2] 
Veins and arteries both have a similar three-layer structure which contain smooth 
muscle that is regulated by the sympathetic nervous system. In veins, nerves are distributed 
throughout the medial smooth muscle coat, often in close apposition (50 nm) to smooth 
muscle cells. In arteries, nerves are located at the adventitial-medial border, few closer than 
2 nm to smooth muscle cells, often with interposing connective tissue and Schwann cell 
processes.[3] When necessary, the sympathetic nervous system signals arteries to relax or 
contract, which changes the lumen size of the lumen and thereby regulates blood flow and 
also affects blood pressure.  
The autonomic nervous system is often defined as a motor neuronal system, 
generally concerned with involuntary body functions, in contrast to the somatic nervous 
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system, which has both motor and sensory neurons responsible for voluntary muscle 
function and general sensation. The autonomic nervous system innervates smooth muscle, 
cardiac muscle, and glands. Physiologically, smooth and cardiac muscles are not completely 
dependent on autonomic motor neurons for contraction. The first-order neuronal cell body 
is located in a central nervous system nucleus, and its fiber (axon) travels peripherally to 
synapse with a second-order neuron, which is located in a peripheral nervous system 
ganglion. In the peripheral nervous system, the larger diameter axons are surrounded by a 
lipid-rich myelin sheath formed by the Schwann cells. Many nerve fibers in the central and 
peripheral nervous system are unmyelinated. In the peripheral nervous system, however, 
even the unmyelinated fibers are enveloped in Schwann cells. The Schwann cell’s plasma 
membrane does not spiral repeatedly around the fiber as it does in a myelin sheath, but 
folds once around each fiber and somewhat overlaps itself along the edges. Most nerve fibers 
travel through individual channels in the Schwann cell, but small fibers are sometimes 
bundled together within a single channel.[4] The Schwann cells (in the peripheral nerves) 
and the satellite cells (in the ganglia) are glial cells (supporting cells) of the peripheral 
nervous system. Glial cells provide support and protection for neurons.  They are thus 
known as the "supporting cells" of the nervous system.  The four main functions of glial cells 
are: to surround neurons and hold them in place, to supply nutrients and oxygen to neurons, 
to insulate one neuron from another, and to destroy and remove dead neurons.[5, 6] 
The small arteries and arterioles are responsible for the major part of the total 
resistance to blood flow in the circulatory system. Normally these vessels are maintained in 
a state of functional constriction (vascular tone) determined by the interaction between 
intrinsic (myogenic tone) and extrinsic (neurotransmitters, hormones, autacoids, and 
products of metabolism) factors. Myogenic tone is a property of arteriolar smooth muscle 
that is independent of any other influence and is the reference tone for the control of 
vascular resistance by extrinsic factors. Neurogenic mechanisms occupy a central position 
in the normal regulation of vascular tone and coordinating the degree of transient changes 
in vascular tone in many regions and organs, enable the rapid redistribution of blood flow 
to areas functionally important to specific activities. 
The renin-angiotensin-aldosterone system plays an important role in regulating 
blood volume and systemic vascular resistance, which together influence cardiac output and 
arterial pressure.[7] Renin, which is primarily released by the kidneys and also by other cell 
types,[8] stimulates the formation of angiotensin in blood and tissues, which in turn 
stimulates the release of aldosterone from the adrenal cortex.[9, 10] Angiotensin II 
facilitates noradrenaline release from sympathetic nerve endings and inhibits 
noradrenaline re-uptake by nerve endings, thereby enhancing sympathetic adrenergic 
function.[11] 
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1.2 Autonomic Nervous System 
 
The autonomic nervous system plays an important role in the regulation of cardiac 
and vascular function. The sympathetic division is the most important nervous division of 
the autonomic nervous system influencing both the whole-body hemodynamics and the 
local vascular tone in many areas. The activity of sympathetic neurons usually elicits 
vasoconstriction roughly proportional to the level of neural activity. This vasoconstriction 
is determined by various combinations of noradrenaline, neuropeptides, and purines.[12] 
The sympathetic nerves that originate in the spinal cord run through the spinal cord, where 
they synapse with preganglionic cell bodies. From these cell bodies run preganglionic fibers 
that synapse with the cell bodies of postganglionic sympathetic fibers (Figure 2). 
Acetylcholine is the neurotransmitter within these ganglia, and the acetylcholine 
binds to nicotinic receptors on postganglionic neurons. From these neurons arise relatively 
long postganglionic fibers that travel to their target organ and release noradrenaline as the 
primary neurotransmitter. Some of the preganglionic sympathetic fibers, instead of 
synapsing within paravertebral ganglia, synapse in prevertebral ganglia located within the 
abdomen (celiac, superior mesenteric, and inferior mesenteric ganglia). Postganglionic 
sympathetic fibers then travel from the prevertebral ganglia to innervate tissues, such as 
blood vessels, where they release noradrenaline as the primary neurotransmitter. 
Therefore, sympathetic postganglionic fibers can originate in either paravertebral or 
prevertebral ganglia (Figure 2).  
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Figure 2 – Schematic representation of autonomic nervous system regulation of cardiac and 
vascular function. (adapted from Cardiovascular Physiology Concepts, Richard E. Klabunde, 
Lippincott Williams & Wilkins) 
 
 
Activation of sympathetic adrenergic nerves in the heart releases noradrenaline that 
binds to adrenergic receptors (primarily beta-adrenoceptors), increasing heart rate, 
contractility and velocity of electrical impulse conduction. Together, these changes increase 
cardiac output and arterial blood pressure. Sympathetic adrenergic activation also 
constricts blood vessels, through the actions of noradrenaline binding to alpha-
adrenoceptors leading to increase of arterial blood pressure. Therefore, the cardiovascular 
effects of vagal activation are primarily mediated through the heart, whereas sympathetic 
activation affects both the heart and vasculature. Preganglionic sympathetic nerves that 
synapse in the adrenal glands stimulate catecholamine release that circulates in the blood 
and affect heart, blood vessels and other organs by activating adrenergic receptors.[13, 14] 
Moreover, under basal resting conditions, vagal and sympathetic adrenergic nerves are 
tonically active. In the heart, because vagal influences override sympathetic effects, there is 
a resting vagal tone that is responsible for maintaining a low heart rate at rest. In contrast, 
most blood vessels, which have little or no vagal innervation, are dominated by sympathetic 
adrenergic influences the sympathetic vascular tone, at rest. 
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1.3 Sympathetic Neurotransmission 
 
Noradrenaline is the classical neurotransmitter, released from sympathetic nerve 
terminals and is responsible for tonic and reflexive changes in cardiovascular tones. 
Noradrenaline is one of the catecholamine neurotransmitters that are synthesized from 
tyrosine by three consecutive enzymatic steps. While tyrosine hydroxylase is the enzyme 
responsible for the first step of catecholamine biosynthesis, converting tyrosine to l-dopa 
(the enzymatic rate-limiting step in catecholamine synthesis), and is expressed in all 
catecholamine neurons, dopamine-β-hydroxylase is the one responsible for conversion of 
dopamine to noradrenaline and is specifically expressed in noradrenergic neurons (Figure 
3).  
A presynaptically localized noradrenaline transporter retrieves released noradrenaline to 
limit the spread and duration of synaptic excitability and allows repackaging of 
noradrenaline into synaptic vesicles. During sympathetic discharge, noradrenaline 
produces vasoconstriction by activating α-adrenoceptors located on vascular smooth 
muscle. 
Most of the noradrenaline contained in adrenergic nerves is stored in granular 
vesicles. Two types of granular vesicles, small and large dense-cored vesicles, both storing 
noradrenaline, have been identified. Vesicles generated near the Golgi apparatus, in cell 
bodies, travel by axonal transport to the nerve terminals. Noradrenergic vesicles may also 
be formed, by endocytosis, within the axons. Noradrenaline is believed to be stored in the 
vesicles in a complex with adenosine triphosphate (ATP), but the vesicles also contain 
enzymes involved in noradrenaline synthesis, and other proteins. It is currently accepted 
that the ATP released together with noradrenaline from sympathetic nerves may act as a 
sympathetic cotransmitter.[15, 16] Noradrenaline taken up into the axoplasm is subject to 
two fates, translocation into storage vesicles and deamination by monoamine oxidase. The 
combination of enzymatic breakdown and vesicular uptake constitute an intraneuronal way 
to keep axoplasmic noradrenaline concentrations very low. Sympathetic stimulation 
releases noradrenaline, and binding of noradrenaline to adrenoceptors on cardiovascular 
smooth muscle cells causes the cells to contract.  
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Figure 3 – Noradrenaline synthesis, storage, release and action. (adapted from Cardiovascular 
Pharmacology Concepts. Richard E. Klabunde. Lippincott Williams & Wilkins, Second Edition) 
 
 
Sympathetic vascular innervation varies widely among vascular beds, with dense 
innervation present on resistance vessels. The density of sympathetic nerves increases as 
the arterial caliber decreases, so that small arteries and arterioles, the smallest nutrient 
vessels possessing smooth muscle cells, have the densest innervation. Sympathetic 
stimulation in these beds produces profound vasoconstriction. Different stressors can elicit 
different patterns of sympathoneural outflows and therefore differential noradrenaline 
release in the various vascular beds. Local sympathoneural release of noradrenaline also 
markedly affects cardiac function and glandular activity. 
A search for new transmitters, other than acetylcholine and noradrenaline, was 
prompted by the discovery that nerves that relax some smooth muscles did not involve the 
release of noradrenaline or acetylcholine. A variety of nonadrenergic, noncholinergic 
transmitters were identified, including ATP, vasoactive intestinal polypeptide, nitric oxide 
(NO), and neuropeptide Y. The notion of the presence of multiple transmitters is now firmly 
established becoming clear that within a single neuron multiple transmitter systems may 
exist, and that within a given ganglion the variety and pattern of neurotransmitters may be 
quite extensive.  
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1.3.1 Sympathetic Neurotransmission: NA/ATP co-transmission 
 
Purinergic neurotransmission expands the cotransmission subject. ATP is a 
primitive extracellular signaling molecule and is now established as a cotransmitter in most 
nerve types both in the peripheral and central nervous systems. There is purinergic 
cotransmission together with noradrenaline and neuropeptide Y, from sympathetic nerves; 
with acetylcholine, from parasympathetic nerves; with calcitonin gene–related peptide and 
substance P, from sensory-motor nerves, with nitric oxide and vasoactive intestinal 
polypeptide, from enteric nerves and with glutamate, dopamine, noradrenaline, g-
aminobutyric acid, and 5-hydroxytryptamine, from subpopulations of central neurons.[17] 
Sympathetic purinergic cotransmission has been demonstrated in a variety of blood vessels 
and the proportion of noradrenaline to ATP is extremely variable in the sympathetic nerves 
supplying different blood vessels.[18-20] ATP contributes to vasoconstriction produced 
after activation of the perivascular nerves in SHR. This involves a synergistic interaction 
with noradrenaline to causes enhanced arterial vasoconstriction, which may contribute to 
the hypertension.[21] 
Distinct presynaptic and postsynaptic mechanisms are observed: ATP is in high 
concentration in sympathetic synaptic vesicles and, after release, is rapidly catabolized to 
other adenosine derivatives.[22] 
 
 
1.4 Adenosine 
 
Adenosine is a naturally endogenous occurring purine nucleoside formed by the 
degradation of ATP (Figure 4) during energy-consuming processes. ATP is the primary 
energy source in cells for transport systems and many enzymes. Most ATP is hydrolyzed to 
ADP, which can be further dephosphorylated to AMP. Most ADP and AMP formed in the 
cell are rephosphorylated in the mitochondria by enzymatic reactions requiring oxygen. If 
there are large amounts of ATP hydrolyzed, and especially if there is insufficient oxygen 
available (i.e., hypoxia), then some of the AMP can be further dephosphorylated to 
adenosine by the cell membrane associated enzyme, 5'-ectonucleotidase.  
Adenosine is rapidly transported into red blood cells (and other cell types) where it 
is rapidly deaminated, by adenosine deaminase, to inosine, which is further broken down 
to hypoxanthine, xanthine and uric acid, which is then excreted by the kidneys. Adenosine 
deamination also occurs in the plasma, but at a lower rate than that occurring within cells. 
Adenosine can be acted on by adenosine kinase and rephosphorylated to AMP. This salvage 
pathway helps maintain adenine nucleotide pools in the cell. Extracellular concentrations 
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of adenosine are increased when energy demands exceed oxygen supply that is, during 
ischemia.[23]  
 
  
 
  
 
Figure 4 - Schematic representation of adenosine formation, metabolism and transport, and G-
protein coupled adenosine receptors (rectangles representing A1, A2A, A2B, and A3 receptors). 
Neurons can release adenosine and adenosine-tri-phosphate (ATP). All cell types express adenosine 
receptors, adenosine transporters (cylinder), and ecto-nucleotidases that convert ATP into 
adenosine. ADP, adenosine-di-phosphate; AMP, adenosine-mono-phosphate; SAH, S-adenosyl-
homocysteine; 5′-N, 5′-nucleotidase; AK, adenosine kinase; ADA, adenosine deaminase; SAHH, S-
adenosyl-homocysteine hydrolase. Activation of adenosine receptors either inhibits (A1/3 receptors) 
or stimulates (A2A/2B receptors) adenylate cyclase and the cyclic AMP (cAMP) pathway. (adapted from 
Landolt HP et al, 2012) 
 
 
Adenosine modulates many physiological processes through activation of four 
subtypes of G protein–coupled membrane receptors: A1, A2A, A2B, and A3 (Figure 4).[24] It 
is well established that adenosine effects occur via activation of A1, A2A, A2B, and A3 
adenosine receptors classically considered to be coupled to Gi/o, Gs, Gs/Gq and Gi/o/Gq, 
respectively.[25] Adenosine receptors are broadly grouped into two main categories: A1 and 
A3 receptors, which couple to inhibitory G proteins, and A2A and A2B receptors, which couple 
to stimulatory G proteins. However, adenosine receptors are pleiotropic; they can couple 
with various G proteins and transduction systems according to their degree of activation 
and their particular cellular or subcellular location.[26]  Its physiologic importance depends 
on the affinity of these receptors and the extracellular concentrations reached. Adenosine 
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may have tonic actions even during physiologic conditions, mostly through activation of 
high-affinity A1 and A2A receptors.[27, 28] 
Membrane transporters are responsible for the uptake of essential nutrients, 
modulation of concentrations of physiologically relevant chemicals, and active release of 
substances such as signaling molecules.[29] Transmembrane transport is a critically 
important physiological process in all cells and is likely to have evolved early to allow for 
controlled uptake and release of nonlipophilic compounds. Nucleoside transporters 
constitute a family of membrane proteins with different pharmacological and kinetic 
properties.[30] To date it is accepted that there are two types of transporters: Equilibrative 
Nucleoside Transporters (ENT) and Concentrative Transporters (CNT). The ENT promote 
equilibrative bidirectional transport processes driven by chemical gradients by facilitated 
diffusion. ENT are present in most, possibly all, cell types. They might mediate adenosine 
transporter in both directions, depending on the concentration gradient of adenosine across 
the plasma membrane. Until the present day, there are four subtypes described: ENT1, 
ENT2, ENT3 and ENT4.  The CNT carry out active inwardly directed concentrative 
processes, driven by the Na+ electrochemical gradient: Na+-dependent. CNT are expressed 
in a tissue-specific fashion. Three subtypes were described: CNT1, CNT2 and CNT3.[31] 
After stimulation, released adenosine is quickly transported back into cells by an 
energy-dependent uptake mechanism, which is part of a purine salvage pathway designed 
to maintain intracellular levels of ATP. The intra and extracellular concentration of 
adenosine is determined, nearby their receptors, by the existence and function of the 
transporters. Adenosine transporters contribute to the intra and extracellular concentration 
of adenosine, modulating its concentration in the vicinity of its receptors.[32-34] The 
effectiveness of this adenosine transport system is species dependent. It is particularly 
active in humans, and it is mainly responsible for the extremely short half-life of adenosine 
in human blood. Adenosine mechanisms are the target of commonly used drugs acting by 
blockade of adenosine reuptake, thus potentiating its actions or antagonizing adenosine 
receptors. Adenosine receptors are ubiquitous and, depending on their localization, may 
mediate opposite effects. This phenomenon is particularly evident in the interaction of 
adenosine and the autonomic nervous system; adenosine can produce either inhibition or 
excitation of autonomic neurons.[35] Adenosine inhibits the release of neurotransmitters 
putatively through presynaptic A1 receptors both in the brain and periphery. This is true for 
practically all neurotransmitters studied, including noradrenaline and acetylcholine. 
Interstitial levels of adenosine are elevated under conditions of increased metabolic 
demand (exercise) and decreased energy supply (ischemia), reaching physiologically 
relevant concentrations. Sympathetic activation leads to systemic vasoconstriction, increase 
in blood pressure, and improved perfusion pressure. This systemic vasoconstriction would 
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be deleterious to the ischemic organ if not for the simultaneous local inhibitory actions of 
adenosine, which produce vasodilation and inhibit noradrenaline release. These actions are, 
for the most part, circumscribed to the local ischemic tissue so that it is protected from 
sympathetically mediated vasoconstriction while it benefits from the improved perfusion 
pressure. Adenosine provides a link between local mechanisms of blood flow autoregulation 
and systemic mechanisms of autonomic cardiovascular regulation.[36]  
Adenosine is released into the extracellular space and signals to restore the balance 
between local energy requirements and energy supply. Endothelial cells interact with 
adenosine mechanisms in many different ways. Endothelial cells are known to have a very 
active adenosine metabolism, characterized by a large capacity for uptake and release of the 
nucleoside, [37, 38] and can be an important source of adenosine released during 
ischemia.[39] Conversely, adenosine may modulate endothelial function via activation of 
cell membrane receptors. The precise nature of the interaction between adenosine receptor 
subtypes and endothelial cells and their role in the regulation of endothelial function is not 
completely understood. However, adenosine-induced endothelial cells production of nitric 
oxide is recognized. 
 
 
1.5 Nitric Oxide 
 
The greatest surprise in the study of autonomic neuroeffector transmission, after the 
discovery that transmitters other than noradrenaline and acetylcholine exist, was the role 
of endothelial cells in the relaxation of arterial smooth muscle. This pointed to the existence 
of a substance that, when released from endothelial cells, acts on vascular smooth muscle 
cells to relax them. The subsequent identification of this substance as nitric oxide led to the 
discovery that nitric oxide is an important transmitter at some autonomic neuromuscular 
junctions.[40, 41]  
Nitric oxide is one substance proposed to act as a neurotransmitter in the autonomic 
nervous system and is very different from the classical neurotransmitters, noradrenaline 
and acetylcholine. NO is a free radical and potentially very toxic. It passes freely through 
membranes and, thus, cannot be stored in vesicles for release during an action potential. In 
addition, it cannot act in a stereospecific way on postjunctional receptors on the target 
membrane to produce a response. It is now known that NO does act as a neurotransmitter 
within the autonomic nervous system, particularly within the parasympathetic and enteric 
nervous systems. NO relaxes smooth muscle by activating soluble guanylate cyclase, which 
increases cGMP levels. Moreover, the complexity of autonomic control and the range of 
mechanisms available to peripheral sympathetic and parasympathetic neurons and their 
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targets are expanded by gaseous molecules (NO) and endothelium released peptides. Also, 
central nervous system centers involved in autonomic control contain NO synthase, and 
evidence suggests that NO can mediate either sympathoinhibition or sympathoexcitation. 
Peripherally, NO exerts tonic vasodilation and mediates acetilcholine-induced vasodilation, 
as well as catecholamine release and action. Nitrergic neurotransmission has been 
demonstrated in the gastrointestinal, urogenital, and cardiovascular systems and its loss 
has also been implicated in a variety of pathological conditions.  
 
 
 
Figure 5 - Synthesis of nitric oxide by Nitric Oxide Synthases (NOS) isoforms. 
 
 
NO is synthesized by the enzyme nitric oxide synthase (NOS), which can exist in 
three isoforms (Figure 5). The isoform involved in nitrergic neurotransmission in the 
autonomic nervous system is nNOS. The other sources of NO are endothelial NOS (eNOS) 
in the endothelium of blood vessels and inducible NOS (iNOS), which is expressed as part 
of an immune response.  
The neuronal isoform of nitric oxide synthase (nNOS) is a highly complex enzyme 
(Figure 6) that exists as a dimer, in which each monomer consists of two enzymes in one. 
One end, the reductase domain, produces electrons during the conversion of reduced 
NADPH to NADP. Electrons are passed along the enzyme by flavin cofactors until they reach 
the oxygenase domain. An important region, the calmodulin binding region, links the two 
domains. In the oxygenase domain there is a heme-binding site. In the presence of 
electrons, heme and O2, L-arginine is converted to citrulline, resulting in NO synthesis in a 
highly regulated, Ca2+-dependent, manner. At basal Ca2+ concentrations within the nerve, 
nNOS is inactive.[42] During an action potential, intracellular concentrations of Ca2+ 
increase resulting in the binding of calmodulin to nNOS and activation of the enzyme. Once 
activated, nNOS converts L-arginine to citrulline and NO.  
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Figure 6 - Neuronal isoform of nitric oxide synthase. nNOS contains a reductase domain and a 
oxygenase domain which are separated by a calmodulin (CaM) binding motif. nNOS is active in 
dimeric form. (from Nitric Oxide Contribution in the CNS: a NO brainer, May O.) 
 
 
The most important step in demonstrating nitrergic neurotransmission has been the 
development of L-arginine analogs that can inhibit NO synthesis such as the non-selective 
NG-nitro-l-arginine methyl ester (L-NAME) and the selective Nω-propyl-L-arginine 
hydrochloride (nNOS inhibitor) and L-NIO dihydrochloride (eNOS inhibitor). NO cannot 
be stored but reaches the postjunctional target by diffusion. Drugs have been developed that 
act as NO donors (e.g. sodium nitroprusside and diethylamine NONOate), and these have 
demonstrated that exogenous NO can mimic the effects of nitrergic neurotransmission. NO 
reacts with hemoglobin or other reactive species such as superoxide anions, both of which 
inhibit neurotransmission or the response to NO donors. Once NO enters the postjunctional 
smooth muscle cell, it produces a response by interacting with the soluble guanylate cyclase. 
NO binds to its heme group, resulting in the activation of the enzyme and production of 
increased levels of cyclic guanosine monophosphate, which causes relaxation of smooth 
muscle. Once the physiologic stimulus of the action potential has ended, Ca2+ levels in the 
nerve return to low resting levels and NO synthesis stops. Therefore, the amount of NO 
synthesized in autonomic nerves does not reach toxic levels.[42, 43] NO, itself, is difficult 
to detect or measure however, the capacity to synthesize NO can be readily demonstrated 
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in the autonomic nervous system by immunohistochemical localization of nNOS. nNOS has 
been localized in both sympathetic and parasympathetic preganglionic neurons and is 
particularly prominent in the enteric nervous system, where it is localized in the myenteric 
and submucosal plexuses. nNOS has also been demonstrated in perivascular nerves 
supplying many blood vessels. Functional studies have demonstrated nitrergic 
neurotransmission throughout the cardiovascular, urogenital, respiratory, and 
gastrointestinal systems.[44-47] NO can function either to cause direct inhibition of smooth 
muscle or as a neuromodulator by inhibiting excitatory transmission.  
An endothelium-derived relaxing factor has been shown to be NO. The vascular 
endothelium synthesizes NO from L-arginine and this action is catalyzed by the action of 
NO synthases, of which two forms are present in the endothelium. Endothelial eNOS is 
highly regulated, constitutively active and generates NO in response to shear stress and 
other physiological stimuli and is responsible for most of the vascular NO· produced.[48] 
Inducible iNOS is expressed in response to immunological stimuli, is transcriptionally 
regulated and, once activated, generates large amounts of NO that contribute to 
pathological conditions. The physiological actions of NO include the regulation of vascular 
tone and blood pressure, prevention of platelet aggregation and inhibition of vascular 
smooth muscle proliferation. Many of these actions are a result of the activation by NO of 
the soluble guanylate cyclase and consequent generation of cyclic guanosine 
monophosphate.[49] An additional target of NO is cytochrome c oxidase, the terminal 
enzyme in the electron transport chain, which is inhibited by NO in a manner that is 
reversible and competitive with oxygen. The consequent reduction of cytochrome c oxidase 
leads to the release of superoxide anion. This may be an NO-regulated cell signalling system 
which, under certain circumstances, may lead to the formation of the powerful oxidant 
species, such as peroxynitrite, that is associated with a variety of vascular diseases. 
A functional eNOS oxidizes its substrate L-arginine to L-citrulline and NO·. This 
normal function of eNOS requires dimerization of the enzyme, the presence of the substrate 
L-arginine and the essential cofactor tetrahydrobiopterin (BH4), one of the most potent 
naturally occurring reducing agents. Cardiovascular risk factors such as hypertension, 
hypercholesterolemia, diabetes mellitus, or chronic smoking stimulate the production of 
reactive oxygen species in the vascular wall. NADPH oxidases represent major sources of 
this reactive oxygen species and have been found upregulated and activated in animal 
models of hypertension, diabetes, and sedentary lifestyle and in patients with 
cardiovascular risk factors. Superoxide (O2·−) reacts avidly with vascular NO· to form 
peroxynitrite (ONOO−).[50, 51] The cofactor BH4 is highly sensitive to oxidation by 
ONOO−. Diminished levels of BH4 promote O2·− production by eNOS (referred to as eNOS 
uncoupling). This transformation of eNOS from a protective enzyme to a contributor to 
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oxidative stress has been observed in several in vitro models, in animal models of 
cardiovascular diseases, and in patients with cardiovascular risk factors. In many cases, 
supplementation with BH4 has been shown to correct eNOS dysfunction in animal models 
and patients. In addition, folic acid and infusions of vitamin C are able to restore eNOS 
functionality, most probably by enhancing BH4 levels as well. 
 
 
 
 
Figure 7 - Potential mechanisms by which cardiovascular risk factors lead to endothelial dysfunction. 
In many types of vascular disease, NADPH oxidases and eNOS are upregulated in parallel. Their 
respective products rapidly recombine to form ONOO−. This oxidizes BH4, the essential cofactor of 
eNOS, and/or produces oxidative damage to the zinc-thiolate cluster of eNOS. Thus, O2 reduction by 
eNOS is uncoupled from NO· formation, and a functional NOS is converted into a dysfunctional O2·− 
-generating enzyme that contributes to vascular oxidative stress. (from Förstermann U , and Münzel 
T Circulation. 2006;113:1708-1714, Copyright © American Heart Association, Inc.) 
 
 
Most cardiovascular risk factors activate molecular machinery in the endothelium 
that results in expression of chemokines, cytokines, and adhesion molecules designed to 
interact with leukocytes and platelets and target inflammation to specific tissues to clear 
microorganisms (Figure 7). The fundamental change involved in this process is a switch in 
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signaling from an NO-mediated silencing of cellular processes toward activation by redox 
signaling. Reactive oxygen species (ROS), in the presence of superoxide dismutase, lead to 
generation of hydrogen peroxide, which, like NO, can diffuse rapidly throughout the cell 
and react with cysteine groups in proteins to alter their function. It is intriguing that eNOS, 
which normally helps maintain the quiescent state of the endothelium, can switch to 
generate ROS in appropriate circumstances as part of endothelial activation. This is termed 
eNOS uncoupling, and results in superoxide formation if the key cofactor 
tetrahydrobiopterin is not present, or generation of hydrogen peroxide if the substrate L-
arginine is deficient. Thus, the ability of eNOS to regulate both the quiescent and activated 
endothelial phenotype puts this enzyme at the center of endothelial homeostasis. 
 
 
1.6 Hypertension  
 
 Globally cardiovascular disease accounts for approximately 17 million deaths a year, 
nearly one third of the total. Of these, complications of hypertension account for 9.4 million 
deaths worldwide every year. Hypertension is a global public health issue. Hypertension, 
also known as high or raised blood pressure, is a condition in which the blood vessels have 
persistently raised pressure. The higher the pressure in blood vessels the harder the heart 
has to work in order to pump blood. If left uncontrolled, hypertension can lead to a heart 
attack, an enlargement of the heart and eventually heart failure. Blood vessels may develop 
aneurysms and weak spots due to high pressure, making them more likely to clog and burst. 
The pressure in the blood vessels can also cause blood to leak out into the brain. This can 
cause a stroke. Hypertension can also lead to kidney failure, blindness, rupture of blood 
vessels and cognitive impairment. It contributes to the burden of heart disease, stroke and 
kidney failure and premature mortality and disability.  
 Hypertension is responsible for at least 45% of deaths due to heart disease, and 51% 
of deaths due to stroke. The increasing prevalence of hypertension is attributed to 
population growth, ageing and behavioral risk factors, such as unhealthy diet, harmful use 
of alcohol, lack of physical activity, excess weight and exposure to persistent stress.[52] 
Enhanced activity of the sympathetic nervous system contributes to the pathogenesis and 
maintenance of hypertension. Sympathetic nervous system activity is increased in both the 
developmental and chronic stages of primary hypertension.[53, 54] Animal and human 
studies demonstrate that sustained sympathetic stimulation of the vasculature induces 
smooth muscle cell hypertrophy and hyperplasia, resulting in sustained increases in 
peripheral resistance. These observations indicate that sympathetic activation plays a key 
role in both initiating and maintaining chronic increase of blood pressure.  
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Vascular smooth muscle cell proliferation/hypertrophy is a consequence of the 
complex interaction of intravascular pressure, systemic and local hormones, genetic 
predispositions, and environmental factors. Animal and human studies demonstrate that 
sustained increases in sympathetic activation directly induce vascular remodeling. Many 
studies report greater circulating levels of noradrenaline in patients with hypertension than 
in normotensive control subjects. In normotensive subjects, increased levels of circulating 
noradrenaline generally induce down-regulation of noradrenergic receptors. However, in 
subjects with hypertension, such down-regulation appears not to occur, resulting in 
enhanced sensitivity to noradrenaline. The combination of enhanced sensitivity to and 
increased circulating levels of noradrenaline likely contributes significantly to sympathetic 
nervous system activity-related hypertension.  
Specific animal models for studying cardiovascular diseases conditions can help 
support research efforts towards finding the necessary cures. The Spontaneously 
Hypertensive Rat (SHR) model is the most commonly used genetically hypertensive rat 
model and also recognized a model of endothelium dysfunction.[55-57] 
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AIMS 
 
The present study intends to clarify if endogenous adenosine and nitric oxide have a 
role in the modulation of sympathetic activity and if this role is preserved in hypertensive 
individuals. On the other hand, and since endothelium derived substances have higher 
impact in vascular tonus, it has been hypothesised that endothelium dysfunction may alter 
vascular sympathetic neurotransmission, contributing to increase vascular tone and, 
consequently, blood pressure.  
To address this goal, it was investigated, in intact and denuded arteries, the 
modulatory roles of endogenous adenosine, via activation of adenosine A1 or A2A receptor 
subtypes, and NO, generated by endothelial NOS (eNOS) and neuronal NOS (nNOS), in 
sympathetic vascular neurotransmission. It was also evaluated if their effects could be 
somehow compromised in mesenteric and tail arteries from spontaneously hypertensive 
rats, an animal model exhibiting endothelium dysfunction and hypertension. Additionally, 
the regional distribution/localization and the relative amount of membrane proteins, 
namely adenosine receptors (A1 and A2A) and enzymes, such as neuronal nitric oxide 
synthase and tyrosine hydroxylase, present in adventitia layer was also determined in both 
mesenteric and tail arteries of the two animal strains (Wistar Kyoto, WKY and 
spontaneously hypertensive rats, SHR). 
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ABSTRACT 
 
Receptors are the molecular targets through which drugs produce their beneficial 
effects in a disease state. Receptors location, in the cell membrane or within the cell, 
contributes for the understanding of the subsequent signalling events triggered by their 
activation. The subcellular localization and physiological functions of receptors are closely 
related and thus it is crucial to precisely determine the distribution of different molecules 
inside the intracellular structures. This is usually studied by fluorescence microscopy and 
posterior evaluation of the colocalization of the molecule of interest in a definite region in 
the cell. Laser Scanning Confocal Microscopy (LSCM) imaging is a powerful tool allowing 
to distinguish a variety of unexpected locations for receptors, manly in subcellular locations 
such as mitochondria, lysosomes, nuclei[1] turns crucial rethinking the current knowledge 
of the pharmacological role ascribed to receptors. Moreover, the use of fluorescent ligands 
in tissues will also be addressed since it allows a multidimensional analysis and provides 
new insights to receptor dynamics and intracellular traffic.[2] 
This chapter describes some of the the strengths, limitations and potentialities 
associated with receptors Laser Scanning Confocal Microscopy (LSCM) imaging, giving 
some practical examples concerning our current research line. Emphasis is placed on the 
importance of appropriate image acquisition guiding the reader through the basic and 
advanced knowledge of major quantitative image analysis approaches. Quantitative 
evaluation of receptors in tissues provides information about receptor over, subexpression 
or redistribution contributing for the understanding of the impairment/deregulation 
associated with receptors putative physiological and/or pathophysiological role. 
 
Keywords: receptors distribution, Laser Scanning Confocal Microscopy, molecular 
targets, quantitative evaluation  
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1. INTRODUCTION 
 
In cell biology a structure on the surface of a cell (or inside a cell) that selectively 
receives and binds a specific substance triggering a cellular response is called a receptor. 
Receptors can be divided into four main classes: ligand-gated ion channels, tyrosine kinase-
coupled, intracellular steroid and G protein coupled receptors. The latter represent the 
largest of the several families of plasma membrane receptors, comprising more than a 
thousand genes and regulating virtually all known physiological processes in mammals. 
Because G protein coupled receptors play specific roles in human disease, they have 
provided useful targets for drug development, being, at present, the commonest molecular 
target for currently used drugs. Accordingly, receptor physiology in a specific tissue/organ 
can be better understood if information on the expression of receptors or other type of 
proteins/ligands combined with experiments that allow to establish their respective 
function contributes for an integrative view of ligands/receptors role both in physiology and 
pharmacology. The knowledege of receptors location, distribution and function has been 
advanced through continous improvement of methodologies and equipments. In this sense, 
the first approach developed to establish receptors location was based on the use of 
radioligands and their binding visualized by in vitro autoradiography in tissue sections[3-
5].  However, limitations in the accuracy of this method, at the cellular level, lead to the 
refinement of techniques such as RT-PCR or  Western-blot, classic and fluorescent 
immunohistochemistry microscope visualization.  
 
 
1.1. Fluorescence microscopy 
 
The application of fluorescence microscopy technologies to physiology and 
pharmacology is growing bringing together insights from three separate existing fields 
(chemistry, immunology and histology). Indeed, immunohistochemistry has grown as 
genomics and bioinformatics have provided unique sequences against which to raise 
antibodies for identifying proteins. Vital chromophores indicate localised chemical 
composition such as pH or Ca2+ concentration by changing the characteristics of their 
excitation or emission. Finally, highly selective ligands have been labeled covalently with 
fluorescent moieties to provide the potential for ligand binding studies at the subcellular 
level, thereby providing pharmacologically interesting insights beyond those provided by 
immunohistochemistry. These rejuvenated old technologies are enhanced further by the 
new opportunities offered by luminescent or fluorescent organic ligands found in plants or 
marine organisms. These can be used as conventional chromophores but, more powerfully, 
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can be spliced to known proteins, by genetic manipulation, to provide a covalently bonded 
fluorescent moiety whose chromatic properties can be exploited.  
Fluorescence microscopy, therefore, allows the detailed mapping of 
ligands/receptors in cells/tissues by multiple fluorescent staining.  Fluorescent techniques 
can be divided in two categories: the conventional fluorescent staining and the molecular 
tagging. In the context of receptor biology, these technologies offer the chance to visualise 
receptors, their antagonist or agonist ligands, including natural hormones and 
neurotransmitters, the transducing proteins with which they interact, and the indicators of 
the cellular response that they mediate or modify. 
The majority of studies on G protein coupled receptors rely on qualitative 
determinations where apparent fluorescence increases or decreases in cells are taken as 
changes in receptor fate or activity. Other inportant information can be extracted when 
colocalisation occurs, i.e. two or more antigens staining patterns labeled by corresponding 
antibodies with different excitation spectra, visualized in different colors, overlaps. 
Colocalization correspond to a coexistence of molecules in a very close physical location 
providing  valuable information to clarify their common features. Furthermore, it is of 
upmost importance to find a way of getting quantitative data that will help to define 
magnitude, concentration dependency or time-course of the processes under study. 
Currently, several methodologies, including laser scanning confocal microscopy (LSCM) 
have been used to characterize receptor dynamics: immunohistochemistry and analysis of 
signal transduction pathways, including visualization of protein binding to other molecules 
or their folding by using fluorescence ressonance energy transfer (FRET) or 
bioluminescence ressoance energy transfer (BRET),[6] live-cell imaging, including 
molecular dynamics by fluorescent protein-fusion probes,[7, 8] traffic analysis of individual 
proteins, such as receptors, by fluorescence recovery after photobleaching (FRAP) 
techniques[9] and protein turnover. 
 
 
1.1.2. Laser Scanning Confocal Microscopy (LSCM) 
 
The major application of LSCM in biomedical sciences is imaging of fixed or living 
tissues previously labeled with fluorescent ligands. The reader is referred to Paddock’s 
review,[10] a chapter that will provide an excellent introduction to the principles and 
practices of LSCM. 
The quality of an image dataset acquired by LSCM, depends mainly on two aspects, 
the correct processing of the sample and the microscope performance. Sample processing, 
in turn, depends on several factors such as, fixation, loading of fluorescent dyes or 
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immunostaining, and the correct mounting of the specimen. It is essential to consider the 
preparation of the samples (specimens) as a subject of particular relevance particularly if 
quantitative analysis is on our purpose: procedures, light conditions and magnification 
must be similar. Ideally, from the technical point of view, the specimen calibration step 
(performed by the computer), requires homogeneous specimens in chemical, dimension 
and structural features. Microscope performance is crucial for the quality of image 
acquisition, mainly through its ability to eliminate the “out-of-focus” from thick 
fluorescently labeled specimens. Since the illumination in a confocal microscopy is achieved 
by scanning one or more focus beams of light across the specimen using a laser, the stability 
of this laser, as well as efficient reflecting mirrors and sensitive low noise photodetectors, 
are key factors that need to be considered. Moreover, there have been considerable 
improvements in the digital image systems, now allowing that multiple fluorochromes to be 
imaged simultaneously by frame or, alternatively, sequentially on a line-by-line basis. 
In modern systems such as LSCM, ‘Z’ axis is now usually associated to the 
collection of a series of images of various focal planes that can be, subsequently, used to 
construct 3D representations of the specimen. Sometimes, lower image stacks acquired by 
LSCM have lower voxel intensities when compared with the upper ones, i.e., there is 
intensity attenuation with depth. To reduce this, it is recommended to start the Z series at 
the deepest part of the specimen or, alternatively, it is also possible to correct this problem 
during image processing.[11]  Therefore, it is possible to process images stacks to obtain 
both 2D or 3D reconstruction (by rotating the specimen and imaging it from several 
different angles) of a specimen, from a single view, using algorithms that have been in 
continous improvement. 4D reconstructions are also possible if time is considered. The 
latter is crucial for receptor signalling events or traffic studies such as visualization of 
receptor internalization processes (using tagged fluorescent proteins). LSCM 2D, 3D and 
4D accurate reconstructions of multiple points offer better depth understanding and 
measurement of features located on the specimen. 
 
 
2. Imaging receptors with LSCM: qualitative analysis 
 
Fluorescent ligands bound to receptors can evidence their location and 
pharmacological information such as affinity or proximity between interacting molecules. 
Such information can be obtained, if binding is reversible, overcaming some limitations, 
namely low molecular concentration and diverse location of receptors. As such, relationship 
between receptor location and function are becoming better understood, contributing to 
new insights relative to drug action mechanisms and new therapeutic targets. Nevertheless, 
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spatial precise distribution of receptors and their function relationships are still largely 
unknown, making this an expanded area of study. In the last decade, studies using LSCM 
have been used to better understand the physiological/pathophysiological function of 
receptors, most of them using antibodies to identify, characterize and define the location of 
proteins/receptors, by immunohistochemistry, in different cells[12] and tissues,[13] 
including in vascular tissues.[14] In the vascular wall three layers can be identified (intima, 
media and adventitia), since their cells present different morphologies and different 
functions. In this respect, the use of fluorescent nuclear stain will enable identification of 
cell orientation, number, organization and cell type allowing layer vessel recognition[15, 16]. 
Receptors can be located in any of these cells and may interplay with other receptors, 
enzymes or transporters located in the same cell or in neighbouring cells. In this respect, 
LSCM resolution is crucial to distinguish between two points on a specimen as separate 
entities, which is mainly dependent on the numeric aperture of the objectives, of the 
substage condenser and the wavelength spectrum of light used.[10] 
 
 
 
Figure 1. Laser scanning confocal immunofluorescence images of rat mesenteric artery adventitia 
immunostained for adenosine A1 receptors (rabbit primary polyclonal adenosine A1 receptor antibody 
and a species specific secondary Alexa 647 antibody: red), tyrosine hydroxylase (mouse primary 
monoclonal tyrosine-hydroxilase (TH) antibody and a species specific secondary Alexa 488 antibody: 
green) and DAPI (cell permeable fluorescent minor groove-binding probe for DNA, blue). Scale Bar 
= 20 µm. White open arrows indicates adenosine A1 receptor population in non-neuronal cells while 
white filled arrows indicate adenosine A1 receptor population on the sympathetic nerves. 
 
 
Taken adenosine A1 receptors as an example, it is possible to identify two 
populations of adenosine A1 receptors in images acquired by LSCM (Figure 1A). One 
population is shown to be in the proximity of an enzyme involved in the generation of the 
neurotransmitter, noradrenaline, inside the sympathetic nerves, thyrosine hydroxilase, 
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whereas other receptors are located in non-neuronal cells. This type of identification  is 
possible since qualitative image analysis is a task for which the human eye is well suited, 
once qualitative data is based on recognition patterns (overall arrangements of elements 
within the specimen). 
Such information complements the knowledge that adenosine A1 receptors are 
involved in sympathetic neurotransmission, as previously determined by transmitter 
release[17-19] and vascular reactivity studies.[20-22] On the other hand, the presence of A1 
receptors in non-neuronal cells, evidenced in these images, clearly suggest additional effects 
mediated by this population of A1 receptors. This information further indicates the need to 
identify the type of cells where these adenosine A1 receptors are present. Indeed, since it is 
well known that several types of cells can be found in adventitia, such as  fibroblasts, 
macrophages and other immune cells or peripheral glial cells (Schwann cells),[23] it would 
be valuable to known the type of cell where adenosine A1receptors are present in order to 
clarify their physiological/pathological role. 
Other type of insights on the interplay between receptors and signalling molecules 
can be drawn using LSCM imaging. Indeed, this type of studies can, for instance, reveal 
substances that may influence receptor triggered signalling pathways/events such as 
reactive oxygen species (ROS), nitric oxide (NO), etc. Figure 2 shows two examples of 
images acquired using specific fluorescent probes for NO and ROS (DAF-FM DA and DHE, 
respectively), in the vicinity of adenosine A1 receptors, suggesting the occurrence of an 
interplay between these receptors and those signalling molecules. This type of data can, 
therefore, be correlated with information in the literature to enhance knowledge. The 
example above mentioned correlates well with reported data  indicating that adenosine 
receptor activation promote the increase of ROS generation[24], and can activate eNOS 
leading to an increase of NO production.[25]  
Nevertheless, qualitative analysis may present limitations, for instance, when it is 
required the precise description of differences in staining patterns among sets of tissues 
and/or cells, comparison of staining among experimental groups, etc. In this sense, 
applicability of LSCM imaging observed, per se, is, however, limited because it is perceived 
differently by the eye and thus can frequently be misleading. Under ideal conditions, a 
person with excellent eyesight can distinguish between 30 to 35 levels in comparison to the 
256 or more detected by LSCM, detecting intensity variations invisible to the human eye 
while for a computer, an image is just an array of values of individual pixels (for 8-bit 
monochrome image, this would be a sequence of numbers, with values ranging from 0 to 
255). To take advantage of this ability, i.e., to achieve infomation related with this intensity 
variations, computer assisted methods of image analysis, particularly, quantification is 
required.  
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Figure 2.- Laser scanning confocal immunofluorescence images of rat mesenteric artery adventitia: 
a) immunostained for adenosine A1 receptors (rabbit primary polyclonal adenosine A1 receptor 
antibody and a species specific secondary Alexa 647 antibody: red), DAF-FM DA (cell-permeable 
fluorescent probe for the detection of nitric oxide: green) and DAPI (cell permeable fluorescent minor 
groove-binding probe for DNA, blue); b) immunostained for adenosine A1 receptors (rabbit primary 
polyclonal adenosine A1 receptor antibody and a species specific secondary Alexa 647 antibody: red), 
DHE (cell-permeable fluorescent probe for the detection of superoxide anion: green) and DAPI (cell 
permeable fluorescent minor groove-binding probe for DNA, blue).  Scale Bar = 20 µm. White arrows 
indicate that NO (labeled with DAF-FM DA) or superoxide anion (labeled with DHE) in the vicinity 
of adenosine A1 receptors. 
 
 
3. Imaging receptors with LSCM: quantitative analysis 
 
Notwithstanding the importance of qualitative informations, reliable quantitative 
data related with the expression of receptors (or other type of proteins) can be precious and 
open possibilities, combined with functional data, to new perspectives of study, contributing 
for an integrative view of receptors/proteins, both in physiology and pharmacology. 
Quantification is crucial for the understanding of physiopathological roles of receptors, 
particularly in disease states where it has been reported that specific receptors types are sub 
a) 
b) 
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or overexpressed.[1, 22, 26-28] Until recently, few studies have addressed the extraction of 
quantitative information on the expression/presence of receptors,[29-31] mostly due to 
methodological difficulties. In this sense, there are several image analysis software 
commercial or freely available (such as Metamorph, PAQI, Image J) allowing automated or 
semiautomated image analysis to quantify one or more receptors/protein types through 
particle counting, area determination and/or intensity measurement. Nevertheless, the 
quantification algorithm will depend on the specificities of the immunohistochemical 
protocols used and the aims of the study. Therefore, adjustments in the quantification 
procedures may be required, leading to procedures customization, to obtain valid 
segmentation profiles of the object of interest. Only through an adequate and criterious 
validation process it is possible to ensure that the methodology application is unbiased, 
credible and reliable[32]. Image processing can require optimization, adjustments, the use 
of filters, histograms, segmentation/thresholding and stack projections.  
Another important aspect that should be considered is the time (duration) of the 
observation since this leads to fluorophores consumption which is critical when the 
parameter to be quantified is fluorescence intensity. Fluorescence intensity and bleaching 
of fluorophores can be influenced by several factors, namely mounting medium, power of 
excitatory light, etc. Other aspect that should be taken into consideration in LSCM is 
photobleaching since[33] the higher power and the focused beam induce enhanced fading 
of the specimen. Strategies to minimize these problems include changing experimental 
conditions related with fluorophores, such as increasing fluorophores concentration, use of 
antifade agents in mounting media or use of fluorophores resistant to bleaching. 
The quality of the original data is crucial for measurement accuracy and depends 
on the resolution of the microscope and the amount of light detected. Digital images quality 
can be assessed using scatter graphs comparing the correlation of an image of a single 
fluorophore with a second image of the some fluorophore. Pearson’s correlation coefficient 
can be used as a quantitative measure of quality to correct the measured colocalization of 
two flurophores. Depending of the type of study other correlation measurements may be 
needed, and are compiled in the JACoP plugin for Image J. Additionally, a proper 
preparation of images for coefficients calculations, and correct interpretation of obtained 
results will determine the sucess of a quantitative study.[34, 35] 
Quantification algorithms can be increasingly complex according to the study aims, 
namely if the researcher wants to segment staining and threshold adjacent but not co-
localized objects of interest (proteins, signaling molecules, receptors, etc). This latter aspect 
is directly related with the LSCM resolution (see above), but may also depend on the study 
features, i. e, if the researcher want to evaluate the colocalization profiles or molecules 
trafficking.  
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The complexities described above have impaired quantitative studies concerning 
receptors to be widespread. If we take images depicted in Figure 1A as an example, 
quantification procedures require an algorithm that includes instructions for the 
measurement of the surface area and intensity of sympathetic nerve terminals, receptors 
and receptors on the sympathetic nerve terminals. This algorithm allows to accurately 
segment and threshold adjacent but not co-localized proteins, tyrosine hydroxylase and 
adenosine A1 receptors (Table 1) and was designed to run in PAQI platform (CEMUP, Porto, 
Portugal). 
After applying this algorithm, the appropriate calculation coefficients were 
performed and results are (in pixels/µm2): total sympathetic nerve fluorescence intensity 
(5.6x105), total adenosine A1 receptors fluorescence intensity (6.1x105), adenosine A1 
receptors overlaid with sympathetic nerves (4.1 x105). These data, clearly evidenced that 
from all receptors quantified 67% were present in sympathetic nerve terminals and 33% 
were found in non-neuronal cells, confirming qualitative data. Concerning disease states 
comparison between values obtained from normal versus pathological state can reveal the 
role of a specific receptor in the disease in study. Moreover, quantitative results concerning 
adenosine A1 receptors located in non-neuronal cells may evidence a pathophysiological role 
attributable to these cells. Depending on the cell type involved (fibroblasts, immune or glial 
cells) more specific conclusions can be drawn.   
Apart from the quantitative analysis of LSCM imaging other ongoing developing 
fluorescence methods allow to extract quantitative measurements, namely the use of 
fluorescent dyes that bind to effector molecules such as Ca2+ (Quin-2, Fura-2, Indo-1 and 
Fluo-3), NO (DAF-2; DAF-FM), ROS (DHE),  Na+ (SBFI), K+ (PBFI), etc. An important 
advance achieved in the last decade was the engineering of fluorescent protein and its use 
as a tag since this approach allowed to better understand the function and location of several 
proteins/receptors improving intracelullar multidimensional analysis. Indeed, two families 
of fluorescent proteins are currently available, the green fluorescent protein (GFP), 
originating from the jelly fish Aequorea victoria and the reef coral fluorescent protein 
(RCFP), originating from reef corals.   
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Table 1. Description of the algorithm steps for the quantification of receptors, 
nerves and of the interception of receptors and nerves 
 
Step 1 (analysis of sympathetic nerves) and step 2 (analysis of adenosine A1 
receptors) 
______________________________________________________________ 
1. Ensure that image is properly prepared, acquired, and processed. 
2. Open Fluorescence images of sympathetic nerves (such as image from Figure 1A, TH) 
or of adenosine A1 receptors (such as image from Figure 1A, A1) 
3. Determining/Setting the threshold intensity reference background/noise (for all 
images) 
4. Obtaining binary image that marks sympathetic nerves or adenosine A1 receptors 
5. Obtaining new image containing only the demarcated areas of sympathetic nerves or 
adenosine A1 receptors and corrected intensity background 
6. Sympathetic nerve or adenosine A1 receptor binary images analysis and determination 
of the surface area of the sympathetic nerves or surface area of attachment of the 
adenosine A1 receptors and the fluorescence intensity on the surface of the sympathetic 
nerves or adenosine A1 receptors, corrected for background. 
______________________________________________________________ 
 
Step 2 (analysis of the receptors on the sympathetic nerves (overlay)) 
______________________________________________________________ 
1. Measurement of the surface area and strength of adenosine A1 receptors on the nerves 
2. Results: Fluorescence images of adenosine A1 receptors; dividing binary images of 
sympathetic nerves; dividing binary image adenosine A1 receptor. 
3. Obtaining image that marks the adenosine A1 receptors on sympathetic nerves 
4. Obtaining image containing only the demarcated areas of adenosine A1 receptors on 
sympathetic nerves and corrected intensity background 
5. The latter is analysed for determination of the surface area of attachment of the 
adenosine A1 receptors on the sympathetic nerves and intensity of fluorescence of the 
adenosine A1 receptors on sympathetic nerves, corrected for background  
______________________________________________________________ 
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The use of fluorescence fusion proteins can be suitable, for instance, for studies 
where their expression is transient or expression levels change overtime (for details see [6]). 
These quantitative studies can be performed statically or in real time imaging. In this sense, 
there are plugins for Image J of upmost usefulness for this purpose. In colocalization studies 
when the two fluorophores colocalization may fluctuate in number or as function of time, 
for example, the Image J plugin “FRET and Colocalization Analyser” can be used. Moreover, 
many fluorescent agonists and antagonist are available for the study of receptors[36], but 
they need to conserve its efficacy and affinity in order to be useful for the study of the 
dynamic processes that include activation, translocation and cell function of receptors, so 
far difficult to address.     
 
 
4. Conclusions 
 
Until recently, most, if not all, pharmacological studies have been based on the 
development of agonist or antagonists and the targeting of the signalling cascades triggered 
by membrane receptor modulation. Nevertheless, several studies have raised the possibility 
that receptors might be located in cellular compartments other than the plasma membrane. 
This perspective can increase the pharmacological understanding of drugs and lead to the 
development of new therapeutic approaches, particularly if their physico-chemical 
properties enable them to cross the plasma membrane. Indeed, in the last 15 years several 
authors have investigated the ocurrence of receptors located inside the cell, both in 
cytoplasmatic organelles[37, 38] and in the nuclei,[39-41] helping in the understanding of 
the subsequent signalling events triggered by their activation. 
Receptors should be viewed as dynamic proteins in constant traffic within the 
plasma membrane or among other organelle membranes where they can be stimulated by 
exogenous or endogenous ligands. Receptor activity is modulated by fine tunning and their 
steady state is balanced by a mechanism involving receptor internalization, through 
endocytosis. Then, receptors are routed to endosomes and they can be either recycled into 
its “active state“ into membranes for repeated receptor activation [38] or be degradated 
inside lysosomes, which lead to the termination of receptor signalling mediated events.[37, 
42-44] 
On the other hand, there is increasing evidence of the presence and role of G 
protein coupled receptors such as endothelin-1, angiotensin II, bradykinin and 
neuropeptide Y receptors in nuclear membrane of many cell types.[40] Therefore, the 
subcellular location and physiological functions of receptors are closely related and justify 
the importance to precisely determine the distribution of different ligands and receptors 
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inside intracellular structures, their trafficking, dimerization or other types of receptor-
protein interactions.  
The combination of new techniques for fluorescent labeling and staining with 
advance fluorescence microscopy has offered new opportunities concerning the analysis of 
cellular dynamic behavior of cellular molecules, such as receptors. These methodologies 
renewed experimental approaches to study receptors location and/or dynamics, allowing 
intracellular visualization and quantification of signalling events triggered by receptor 
activation, through continuous determination of ions (Ca2+, Na+, K+, etc) as well as their 
spatial and temporal concentration variations in single cells or in cell 
compartments/organelles. It is accepted that the use of dye-tagged ligands coupled to real 
3D confocal microscopy is the best methodology for the research and development of new 
drugs  and it can be performed in vitro,  in different cell types, or in vivo using tissue 
sections of treated animals.[45, 46] A even more recent refinement of this technique 
consists in the cytosolic microinjection of dye-tagged ligands before real 3D confocal 
microscopy analysis.   
In summary, available sensitive microscopy equipment, development of 
fluorescent antibodies, tags and probes including for agonists and antagonists, and 
powerful analytical computer-assisted methods is allowing increasing research advances 
concerning location, traffic and function of receptors in different experimental conditions 
including real-time scale. These advances can greatly help researchers to better understand 
intracellular events and receptor physiopathological roles impacting our knowledge of 
health and disease. 
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ABSTRACT 
 
Background 
Increased sympathetic activity has been implicated in hypertension. Adenosine has been 
shown to play a role in blood flow regulation. In the present study, the endogenous 
adenosine neuromodulatory role, in mesenteric arteries from normotensive and 
spontaneously hypertensive rats, was investigated.  
 
Methods and Results  
The role of endogenous adenosine in sympathetic neurotransmission was studied using 
electrically-evoked [3H]-noradrenaline release experiments. Purine content was 
determined by HPLC with fluorescence detection. Localization of adenosine A1 or A2A 
receptors in adventitia of mesenteric arteries was investigated by Laser Scanning Confocal 
Microscopy. 
Results indicate a higher electrically-evoked noradrenaline release from hypertensive 
mesenteric arteries. The tonic inhibitory modulation of noradrenaline release is mediated 
by adenosine A1 receptors and is lacking in arteries from hypertensive animals, despite their 
purine levels being higher comparatively to those determined in normotensive ones. Tonic 
facilitatory adenosine A2A receptor-mediated effects were absent arteries from both strains. 
Immunohistochemistry revealed an adenosine A1 receptors redistribution from sympathetic 
fibers to Schwann cells, in adventitia of hypertensive mesenteric arteries which can explain, 
at least in part, the absence of effect of these receptors in hypertensive arteries.  
 
Conclusion  
Data highlight the role of purines in hypertension revealing that an increase in sympathetic 
activity in hypertensive arteries is occurring due to a higher noradrenaline/ATP release 
from sympathetic nerves and the loss of endogenous adenosine inhibitory tonus. The 
observed nerve-to-glial redistribution of inhibitory adenosine A1 receptors in hypertensive 
arteries may explain the latter effect. 
 
Keywords: mesenteric artery, adenosine, hypertension, noradrenaline 
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INTRODUCTION 
 
Increased sympathetic activity has been implicated in the pathophysiology of 
hypertension since it drives to an enhancement of vasoconstriction.[1,2] Vascular 
sympathetic activity can be regulated by several endogenous substances, such as adenosine. 
Extracellular adenosine can either be released as such, via nucleoside transporters, 
or produced from extracellular catabolism of released adenine nucleotides, namely ATP, 
from distinct cells including neurons. ATP is then sequentially dephosphorylated into ADP, 
AMP and adenosine. [3] Besides its action at the synapse, adenosine may function as a non-
synaptic signalling molecule upon diffusion away from its local of origin influencing 
neurotransmission, inflammation and immune responses [4]. Adenosine effects occur 
through activation of four G-protein coupled receptors, adenosine A1, A2A, A2B and A3 
receptors.[5]  
In vessels, the involvement of adenosine receptors in sympathetic modulation has 
been described both in arteries[6-13] and in veins.[12] A reduced effect mediated by 
selective adenosine A1, but not A2A receptor agonists in sympathetic vascular 
neurotransmission in hypertensive state has been reported.[13] Nevertheless, the 
endogenous adenosine role in vascular sympathetic neurotransmission remains to be 
clarified, particularly whether the endogenous adenosine levels may have a 
pathophysiological impact in hypertensive states. 
We postulate that the effects of endogenously generated adenosine are also impaired 
in hypertensive individuals leading to increased vascular sympathetic activity. The study 
was undertaken in mesenteric arteries from normotensive (Wistar-Kyoto, WKY) and 
spontaneously hypertensive rats (SHR), a well-establish model of hypertension [14,15], to 
determine whether endogenous adenosine has a role in the modulation of sympathetic 
activity and if this role is preserved in hypertensive individuals. Moreover, the regional 
distribution/localization and relative amount of adenosine receptors (A1 and A2A subtypes) 
in the two animal strains was also evaluated. 
 
 
MATERIALS AND METHODS 
 
 Animals 
 
Adult male WKY and SHR (12 weeks old, 270-350 g; Charles River, Barcelona, 
Spain) were used. Handling and care of animals were conducted according to the European 
guidelines (Directive 2010/63/EU) on the protection of animals used for scientific purposes 
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in agreement with the NIH guidelines. This study was carried out in strict accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Committee on the Ethics of 
Animal Experiments of the University of Porto (Permit Number: 13/11/2013). Animals were 
sacrificed using guillotine. Two animals per experiment were used and from each 
mesenteric artery four segments (4-7 mg) were obtained. From each animal, no more than 
two tissue preparations were submitted to identical treatments. 
 
 
Chemicals 
 
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 
41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); desipramine 
hydrochloride, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 7-(2-phenylethyl)-5-amino-
2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine (SCH 58261), S-(4-
Nitrobenzyl)-6-thioinosine (NBTI) and 5-Iodotubericidin (ITU), (8R)-3-(2-Deoxy-β-D-
erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (pentostatin), 
α,β-methylene ADP,  N6-cyclopentyladenosine (CPA), 2-p–(2-
carboxyethyl)phenethylamino-5´-N-ethylcarboxamidoadenosine hydrochloride (CGS 
21680) were purchased from Sigma-Aldrich (Sintra, Portugal). The following antibodies 
were used: rabbit polyclonal anti-A1 (epitope corresponding to amino acids 287-326 
mapping at the C-terminus of human adenosine A1 receptors; sc-28995), anti-A2A (epitope 
corresponding to amino acids 331-412 mapping at the C-terminus of human adenosine A2A 
receptors; sc-13937) were purchased from Santa Cruz Biotechnology, Inc., CA, USA; mouse 
monoclonal anti-tyrosine hydroxilase antibody (TH(45): sc-136100, Santa Cruz 
Biotechnology, Inc., CA, USA and MAB318, Millipore Corporation, CA, USA); anti-glial 
fribillary acidic protein (GFAP) mouse monoclonal antibody (G6171, Sigma-Aldrich, Inc., 
USA) and rabbit GFAP polyclonal antibody (18-0063, Invitrogen, Life Technologies, SA, 
Madrid, Spain). The following fluorescent probes were used: Alexa Fluor® 488 goat anti-
mouse IgG (H+L) antibody, highly cross-adsorbed and Alexa Fluor® 647 goat anti-rabbit 
IgG (H+L) antibody, highly cross-adsorbed (Molecular Probes®) secondary fluorescent 
antibodies (Invitrogen, Life Technologies, SA, Madrid, Spain); vectashield mounting 
medium with DAPI (Vector Laboratories, UK). Stock solutions were made up in 
dimethylsulphoxide (DMSO: 0.01% v/v, final concentration) or ultrapure water and diluted 
in superfusion medium immediately before use. DMSO was added to the superfusion 
medium (final concentration 0.01%), in parallel control experiments. 
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[3H]-Noradrenaline release experiments 
 
Evaluation of [3H]-noradrenaline release experiments was carried out as previously 
described.[9-13] Arteries were pre-incubated in 2 ml Krebs-Henseleit solution containing 
0.1 µmol/L [3H]-noradrenaline (for 60 min at 37ºC) and transferred into superfusion 
chambers, superfused with [3H]-noradrenaline-free medium (1 ml/min; constant rate: 
Krebs-Henseleit solution with desipramine 400 nmol/L to inhibit noradrenaline’s neuronal 
uptake). Two periods of electrical stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo Sachs 
Elektronik, March-Hugstetten, Germany) were applied, S1 and S2, with 30 min intervals 
(t=90 min and t=120 min, respectively). The superfusate was collected each 5 min period 
from 85 min of superfusion onwards. At the end of the experiments (t=130 min), tritium 
was measured in superfusate samples and solubilized arteries (sonicated 1h with 2.5 ml 
perchloric acid (0.2 mol/L)) by liquid scintillation spectrometry (LS 6500, Beckman 
Instruments, Fullerton, USA) after adding 6 ml of a scintillation mixture (OptiPhase ‘Hisafe’ 
3, PerkinElmer, I.L.C., Lisboa, Portugal) to each sample. 
Tissue labelling with [3H]-noradrenaline and evaluation of electrically-evoked tritium 
overflow changes was performed as previously described.[12,13] Effects of agonists (CPA, 
CGS 21680), of antagonists (DPCPX, SCH 58261), and of enzyme (pentostatin, ITU, α,β-
methylene ADP) and nucleoside transport (NBTI) inhibitors were studied. 
 
 
Laser scanning confocal microscopy (LSCM) experiments 
 
Immunohistochemistry procedures were previously described.[13] Briefly, four 
tissue preparations were obtained from each artery and immediately placed in cold 
phosphate buffer solution (PBS; in g/L): NaCl 8.0, Na2HPO4.2H2O 0.77, KCl 0.20, 
KH2PO4 0.19 (pH 7.2). Each preparation was longitudinally opened and fixed 
(paraformaldehyde 4% PBS; 50 min; room temperature). After two 15 min PBS washing 
cycles, artery segments were incubated with primary antibodies raised against rabbit 
polyclonal individual adenosine receptor subtypes (anti-A1 or anti-A2A, 1:200 dilution, 
overnight, 4ºC) and mouse monoclonal anti-tyrosine hydroxilase (TH, 1:10 dilution, 
overnight, 4ºC) or mouse monoclonal anti-glial fribrilary acidic protein (GFAP, 1:200 
dilution, overnight, 4ºC). Thereafter, tissues were incubated with Alexa 647 anti-rabbit and 
Alexa 488 anti-mouse fluorescent secondary antibodies (1:1000 dilution, 1 h, room 
temperature). Negative controls were performed by omitting primary antibodies. After two 
PBS washing cycles, tissue preparations were mounted with antifading agent (vectashield 
mounting medium with DAPI, Vector Laboratories, UK), with the adventitial side facing up.  
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Preparations were visualized with Olympus FluoView FV1000 fluorescence confocal 
microscope system with a x60 oil immersion lens. Stacks of 1 µm thick serial optical images 
were captured from the entire adventitial layer, which was identified by the shape and 
orientation of the nuclei. Image acquisition was performed always under the same laser 
power, brightness and contrast conditions. Adventitia was scanned along each mesenteric 
artery and the resulting images were reconstructed separately for each wavelength.  
 
 
ε-derivatives assay in artery superfusates 
 
1,N6-Etheno (ε)-modified purines have been previously used for purine 
quantification in tissue superfusates. [3,16-19] Briefly, mesenteric artery segments were 
superfused (Krebs-Henseleit, 1ml.min-1) and electrically stimulated twice (S1-S2; 5 Hz, 100 
pulses, 1 ms, 50 mA) 30-min apart ( t=90 min and t=120 min). 5-min superfusates were 
collected and heated at 80ºC. From the collected samples, 910 µL were incubated with 90 
µL of chloroacetaldehyde for 50 min at 70ºC in a dry bath incubator (Heraeus Instruments, 
Hanau, Germany). Reactions were stopped by placing samples on ice. Identification of the 
ɛ-derivatives (ɛ-ATP, ɛ-ADP, ɛ-AMP and ɛ-adenosine) formed in these collected samples 
was confirmed by HPLC using a fluorescent detector (model LS20; Perkin Elmer, 
Beconsfield, UK) at 230 nm excitation and 420 nm emission wavelengths. The stationary 
phase was 5 µm particle size packed in a 250 cm long by 4 mm internal diameter ODS- (C18) 
column and matching 1 cm long by 3.3 mm diameter direct-connect guard column (ACE-
Advanced Chromatography technology, Aberdeen, Scotland) in a gradient HPLC system 
(306 and 811C Gilson, Gilson Medical Electronics, Middleton, WI, USA). The column was 
kept at room temperature (20-22ºC). The mobile phase consisted of a solution of 87 
mmol/L KH2PO4 and 10.6 mmol/L Na2HPO4 (pH 6.0) as buffer A; buffer B was made up 
25% methanol and 75% buffer A. Gradient elution was used according to the following linear 
program: from 0 to 20 min of elution, a convex gradient from 0 % to 100% of Buffer B at a 
flow rate of 1mL/min; from 0 to 3 min of elution, an increase from 0% to 25% of buffer B at 
a flow rate of 1mL/min; from 3 to 7 min of elution, 25% of buffer B at a flow rate of 1mL/min; 
and from 8 to 12 min of elution an increase from 25% to 100% of buffer B at a flow rate of 
1mL/min; from 12 to 20 min of elution, 100% of buffer B at a flow rate of 1mL/min. The run 
time was 20 min and the post-run time 5 min.  
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Data Analysis 
 
Measurement of drug effects on electrically-evoked tritium overflow. 
Electrically-evoked tritium overflow from artery segments incubated with [3H]-
noradrenaline has been shown to reflect action potential-evoked neuronal noradrenaline 
release and drug-induced changes in evoked tritium overflow are assumed to reflect changes 
in neuronal noradrenaline release. Effects of drugs added after S1 on electrically-evoked 
tritium overflow were evaluated as ratios of the overflow elicited by S2 and the overflow 
elicited by S1 (S2/S1). S2/S1 ratios obtained in individual experiments in which a test 
compound A was added after S1 were calculated as a percentage of the respective mean ratio 
in the appropriate control group (solvent instead of A). When the interaction of A, added 
after S1, and a drug B added 5 min before S2, was studied, the “appropriate control” was a 
group in which A alone was used. 
 
Laser Scanning Confocal Microscopy images quantification 
Quantitative analysis of confocal z-stacks images was performed using image 
analysis software (PAQI, CEMUP, Porto, Portugal). Briefly, a sequential routine was 
designed and developed to analyse each fluorescent signal used. PAQI software measured 
the surface area and strength of the fluorescence signal marking the postganglionic nerves, 
the surface area and strength of the fluorescence signal marking the receptors and 
determined the surface area of attachment of the receptors on the nerves as well as the 
intensity of fluorescence of the receptors on nerves (corrected for background).  
 
Quantification of the ɛ-derivatives formed in collected artery superfusates 
The amount of adenine nucleotides and adenosine (pmol/mg of tissue) in each 
collected sample was estimated from calibration curves of purine standards (derivatized as 
described above for the samples), run with every set of 20 samples. 
 
Statistics 
Results are expressed as mean±s.e.m. and n denotes the number of tissue 
preparations. Differences of means were compared for significance using one- or two-way 
ANOVA, followed by post-hoc Holm-Sidak’s multicomparison t test. A P value lower than 
0.05 was considered to denote statistically significant differences. 
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RESULTS 
 
 
Noradrenaline release from mesenteric sympathetic nerve terminals 
 
Stimulation (100 pulses/5 Hz) significantly increased tritium outflow from 
mesenteric artery of both WKY and SHR. In the absence of drugs other than desipramine 
(400 nmol/L), the average basal overflow (b1, fractional release), immediately before S1, was 
similar in WKY (0.070±0.008; n=15) and SHR (0.071±0.003; n=11) mesenteric arteries, 
whereas electrically-evoked tritium overflow (S1, ratio of the total tritium content of the 
tissue) was more pronounced in SHR mesenteric arteries (0.358±0.05; n=11; p<0.05) 
comparatively to those from WKY (0.229±0.037; n=15). In control conditions, basal outflow 
and electrically-evoked tritium overflow remained constant throughout experiments, with 
bn/b1 and Sn/S1 average values close to unity (data not shown).  
 
 
Role of endogenous adenosine in vascular sympathetic neurotransmission 
 
Endogenous adenosine-mediated effects in mesenteric artery sympathetic 
neurotransmission were evaluated by blocking the high affinity adenosine receptor 
subtypes (A1 and A2A) with the selective antagonists, DPCPX and SCH 58261, respectively. 
In the presence of DPCPX (100 nmol/L), a facilitation of electrically-evoked tritium 
overflow was observed (Figure 1). This finding is compatible with the occurrence of a tonic 
inhibition mediated by endogenous adenosine via adenosine A1 receptor activation. 
However, this effect was only observed in WKY mesenteric arteries. SCH 58261 (20 nmol/L) 
did not modify tritium overflow in mesenteric arteries from both strains, discarding the 
occurrence of a putative tonic adenosine A2A receptor-mediated facilitation. Upon reducing 
endogenous adenosine levels by preventing AMP (formed from dephosphorylation of ATP 
released after nerve stimulation) conversion into adenosine, through inhibition of ecto-5’-
nucleotidase (with α,β-methylene ADP, 10 µmol/L), we observed a facilitation of similar 
magnitude of that detected in the absence of tonic adenosine A1 receptor inhibition 
(revealed by DPCPX treatment). Likewise, this effect was only observed in WKY mesenteric 
arteries. 
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Figure 1 - Influence of endogenous adenosine on tritium overflow modulation from WKY and SHR 
MA: interaction with DPCPX, SCH 58261, α,β-methylene ADP or pentostatin. Tissues were 
electrically stimulated (S1-S2: 100 pulses, 5 Hz). Drugs were added after S1 and kept until the end of 
the experiment. Values are mean±s.e.m. from 4-12 segments. Significant differences from the 
appropriate control: *P<0.05; from WKY: ## P<0.001. 
 
 
Pentostatin (10 µmol/L), an adenosine deaminase inhibitor, did not alter the 
electrically-evoked tritium overflow (Figure 2). However, NBTI (5 µmol/L), a bidirectional 
equilibrative nucleoside transporter inhibitor and ITU (100 nmol/L), an adenosine kinase 
inhibitor were able to increase tritium overflow, but only in WKY mesenteric arteries 
(Figure 2). Moreover, the facilitatory effects observed in the presence of ITU or NBTI were 
completely antagonised by SCH 58261 (Figure 2). In contrast, electrically-evoked tritium 
overflow from SHR mesenteric arteries was unaffected by pharmacological manipulation of 
endogenous adenosine levels (Figures 1 and 2). 
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Figure 2 - Effects of NBTI or ITU in the absence or presence of SCH 58261 on the electrically-evoked 
tritium overflow from WKY and SHR MA. Tissues were electrically stimulated (S1-S2: 100 pulses, 5 
Hz). Drugs were added after S1 and kept until the end of the experiment. Values are mean±s.e.m. 
from 4-12 segments. Significant differences from the appropriate control: * P<0.05, * P<0.05; from 
WKY: ## P<0.001; from the inhibitor alone: † P<0.05.  
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ATP and adenosine levels in WKY and SHR mesenteric arteries  
 
Noradrenaline/ATP co-transmission has been demonstrated to occur in mesenteric 
artery.[20,21] Endogenous levels of ATP and adenosine were significantly higher in 
superfusates from SHR mesenteric arteries, comparatively to those of WKY (Figure 3), both 
under basal conditions and after electrical stimulation (5 Hz/100 pulses). Only minute 
amounts of ADP and AMP were found (data not shown). Moreover, stimulation increased 
ATP released amounts comparatively to the amounts observed in basal conditions, but only 
in SHR tissues. Surprisingly, adenosine levels, before and after stimulation, were similar in 
arteries from both strains, although still higher than those of ATP. 
 
 
 
 
Figure 3 - Basal and electrically-evoked ATP (A) and adenosine (B) release in MA of WKY and SHR.  
Tissues were electrically stimulated (S1-S2: 100 pulses, 5 Hz). Significant differences from basal 
conditions: *P<0.05; from WKY: # P<0.05; ##P<0.001. 
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Effects of A1 and A2A ARs agonists on vascular sympathetic neurotransmission  
 
CPA (a selective adenosine A1 receptor agonist, 100 nmol/L) inhibited electrically-
evoked tritium overflow in mesenteric arteries from both strains. This inhibition was more 
pronounced in WKY (63.28±3.9%; n=6; p<0.05) than in SHR (74.70±2.86%; n=14; 
p<0.05). Conversely, the selective adenosine A2A receptor agonist, CGS 21680 (100 
nmol/L), facilitated tritium overflow to similar extent: 123.64±5.18% (n=4; p<0.05) and 
121.62±7.73% (n=4; p<0.05) in WKY and SHR mesenteric arteries, respectively. Effects 
elicited by adenosine receptor agonists were supressed by pre-incubation with the 
corresponding selective adenosine receptor antagonists, DPCPX (100 nM) and SCH 58261 
(20 nM). These results demonstrate that mesenteric arteries from WKY and SHR exhibit 
functional adenosine A1 and A2A receptors, which can be selectively activated by stable 
adenosine analogues. These results suggest that activation of adenosine A2A receptos is 
largely preserved in hypertensive rats but the adenosine A1 receptor-mediated inhibition is 
somehow compromised in these animals. 
 
 
Localization A1 and A2A ARs in vascular sympathetic neurons in the adventitia 
of WKY and SHR mesenteric arteries 
 
In WKY and SHR mesenteric arteries, adenosine A1 receptor immunoreactivity 
showed considerable overlay, but did not co-localize, with the sympathetic neuronal marker 
(TH; Figure 4A), indicating that they might be localized on the same cellular structure 
(postganglionic sympathetic nerves). This agrees with the fact that adenosine A1 receptors 
are membrane receptors while tyrosine hydroxylase (TH) is localized inside sympathetic 
neurotransmitter storage vesicles.[22] 
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Figure 4 - LSCM representative images of WKY and SHR MA exhibiting (A) A1ARs (red), TH (green) 
and overlay of A1-TH immunoreactivities,  nuclei (blue); (B) Relative means of TH, A1 and TH-A1 
overlay expressed as percentage of WKY values. (C) Mean percentage of overlay rate with TH (D) and 
mean percentage of overlay rate with A1 are depicted. Arrows highlight non-neuronal cells. Images 
are reconstructions from 9-28 serial optical sections analyzed using PAQI software. Values are 
mean±s.e.m.; 3-4 animals. Significant differences from WKY: # P<0.05, ## P<0.001. Scale bar = 20 
µm. 
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Adenosine A1 receptor immunoreactivity in non-neuronal cells was also observed, 
particularly in mesenteric arteries from SHR. TH and A1 immunoreactivities in SHR 
exceeds those observed in WKY arteries (Figure 4B). However, overlaid TH and A1 
immunoreactivities were roughly similar in arteries from both strains (Figure 4B). Figure 
4C shows that adenosine A1 receptor and TH overlaid immunoreactivities are markedly 
reduced in SHR comparatively to WKY tissues, when data was normalized by total TH 
immunoreactivity: 70% of sympathetic neurons exhibit adenosine A1 receptor 
immunoreactivity in WKY versus only 40% observed in SHR. Adenosine A1 receptor 
immunoreactivity was also observed in cells other than sympathetic neurons: 33% in WKY 
and 50% in SHR mesenteric arteries (Figure 4A and 4D).  
Similar analysis of adenosine A2A receptor and tyrosine hydroxylase (TH) was 
performed in WKY and SHR mesenteric arteries (Figure 5).  TH immunoreactivity in SHR 
exceeds that observed in WKY (Figure 5B), while A2A-TH overlaid immunoreactivities are 
lower in SHR arteries. Figure 5C shows that A2A-TH, normalized by total amount TH 
immunoreactivity, is significantly reduced in SHR (38%) comparatively to WKY tissues, 
where almost all sympathetic neurons (99% of TH-positive immunoreactivity) also exhibit 
adenosine A2A receptor immunoreactivity. Moreover, the percentage of cells exhibiting 
adenosine A2A receptor immunoreactivity other than sympathetic neurons was similar in 
WKY (77%) and SHR arteries (73%) (Figure 5D). 
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Figure 5 - LSCM representative images of WKY and SHR MA exhibiting (A) A2AARs (red), TH (green) 
and overlay of A2A-TH immunoreactivities,  nuclei (blue); (B) Relative means of TH, A2A and TH-A2A 
overlay expressed as percentage of WKY values. (C) Mean percentage of overlay rate with TH (D) and 
mean percentage of overlay rate with A2A are depicted. Arrows highlight non-neuronal cells. Images 
are reconstructions from 11-20 serial optical sections analyzed using PAQI software. Values are 
mean±s.e.m.; 3-4 animals. Significant differences from WKY: #P<0.05, ## P<0.001. Scale bar = 20 
µm.   
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Localization of A1 and A2AARs in Schwann cells of the adventitia of WKY and 
SHR mesenteric arteries 
 
In the adventitia of mesenteric artery several cell types can co-exist.[23,24] Since we 
have observed adenosine A1 (Figure 4D) and A2A receptor (Figure 5D) immunoreactivities 
outside sympathetic neurons and since these neurons are wrapped with Schwann cells, we 
hypothesized that the non-neuronal cells exhibiting adenosine A1 or A2A receptor 
immunoreactivities were Schwann cells. GFAP (peripheral glial cell marker)[25] 
immunoreactivity overlaid with adenosine A1 (Figure 6A) or A2A (Figure 6B) receptor 
immunoreactivities in the adventitia of both strains. Therefore, in addition to sympathetic 
nerves, Schwann cells also present adenosine A1 and A2A receptors. 
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Figure 6. LSCM images of A1ARs (panel A) and A2AARs (panel B) immunoreactivities in GFAP-
immunoreactive (Schwann) cells located in adventitia of WKY and SHR MA; 3-4 animals. Scale bar 
= 20 µm. 
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DISCUSSION 
 
There is a gap in the knowledge regarding the complex interplay between receptor 
expression and the role of the endogenous neuromodulator, adenosine, on vascular 
sympathetic neurons. This study shows that endogenous adenosine contributes to down-
modulate noradrenaline release from sympathetic neurons through activation of adenosine 
A1 receptors in normotensive mesenteric arteries, but this effect is completely lost in 
hypertensive arteries justifying the observed increase of noradrenaline release. 
In normotensive mesenteric arteries removal of the inhibitory tone of adenosine 
either by inhibiting ecto-5’-nucleotidase or by selectively blocking adenosine A1 receptors 
caused a facilitation of noradrenaline release from stimulated sympathetic neurons up to 
32%. Therefore, it seems that, under physiological conditions, endogenous adenosine 
contributes to restrain transmitter release from stimulated mesenteric arteries via 
activation of inhibitory adenosine A1 receptors, as previously demonstrated.[26] Data also 
indicate that the adenosine A1 receptor inhibitory tonus is mediated predominantly by 
adenosine originated from metabolism of released adenine nucleotides. These results along 
with the observation that the amount of adenosine in superfusates was unaffected upon 
stimulation were rather surprising. Nevertheless, our findings gain physiological 
significance if one considers that inhibitory adenosine A1 receptors operate to restrain 
noradrenaline release under basal conditions, as a consequence of adenosine accumulation 
from hydrolysis of ATP released from neighbouring cells. This scenario may change towards 
putative activation of P2 receptors, along with adenosine receptors, in hypertensive 
arteries[2] a possible scenario if one takes into consideration the increased ATP levels found 
in stimulated SHR superfusates.  
Transmitters release modulation ascribed to extracellular adenosine accumulation 
depends both on its formation and on cellular uptake and deamination.[27-29] We showed 
that adenosine deaminase inhibition failed to modify noradrenaline release, causing minor 
changes in extracellular adenosine accumulation. Interestingly, NBTI was able to increase 
noradrenaline release, suggesting that adenosine uptake may be the dominant adenosine 
inactivation pathway in mesenteric arteries. NBTI enhancement of noradrenaline release 
was antagonised by SCH 58261, indicating that this effect is mediated by adenosine A2A 
receptors, activated by endogenous adenosine (Figure 2). These apparent contradictory 
results, showing that SCH 58261 was unable to modify transmitter release from stimulated 
sympathetic neurons (Figure 1), may be explained due to differences in Kd ascribed to 
inhibitory adenosine A1 and facilitatory A2A receptors, the latter requiring concentrations 
two-fold higher than those required to activate adenosine A1 receptors.[30]  Nucleoside 
transporter inhibition seems to increase extracellular adenosine to levels high enough to 
Manuscript I 
67 
 
activate adenosine A2A receptors, while in its absence the amount of adenosine may be 
insufficient to activate these receptors. Therefore, in conditions that favour extracellular 
adenosine accumulation, this nucleoside may reach concentrations higher enough to 
activate adenosine A2A receptors, as described in other tissues.[27-29] 
To our knowledge, this is the first study demonstrating that the endogenous 
adenosine neuromodulatory role of sympathetic transmission is significantly impaired in 
mesenteric arteries from hypertensive rats. In SHR mesenteric arteries we failed to detect 
both adenosine A1 and A2A receptor mediated effects (after NBTI-induced extracellular 
adenosine accumulation). This is occurring despite the extracellular levels of both ATP and 
adenosine were significantly higher in hypertensive mesenteric arteries than those 
measured in normotensive artery superfusates. These differences on adenosine 
neuromodulation may be explained by changes in adenosine A1 and/or A2A receptors: i) 
activity/desensitization, ii) downregulation or iii) redistribution into other organelle or 
cells. In this regard, we showed, using enzymatically stable and selective adenosine receptor 
agonists, that neuromodulatory activity of adenosine A1 but not of A2A receptors is 
significantly impaired in hypertensive mesenteric arteries.  
Laser scanning confocal microscopy data confirmed previous reports of a 
sympathetic hyperinnervation in hypertensive mesenteric arteries.[31-34] Interestingly, 
increases in the number and thickness of sympathetic nerve fibres observed in SHR 
mesenteric arteries was not accompanied by a correspondent enhancement of adenosine A1 
and/or A2A receptors overlaying these neurons: a decrease of both adenosine A1 (from 70% 
to 40%) and A2A receptors (from 99% to 40%) in sympathetic neurons in hypertensive 
versus normotensive mesenteric arteries was observed. These lower amounts can explain, 
at least in part, the lack of adenosine inhibitory (and facilitatory) tone regulating 
noradrenaline release from stimulated SHR mesenteric arteries, leading to higher 
extracellular noradrenaline levels. 
Data also show, for the first time, that 33% of adenosine A1 receptors and 77% of 
adenosine A2A receptors, in WKY mesenteric artery adventitia, are present in other cells 
than sympathetic neurons (TH-immunoreactive cells). While the amount of adenosine A1 
receptors localized in these cells (Schwann cells) increased to roughly 50% in SHR arteries, 
we observed no changes in the amount of adenosine A2A receptors in arteries from both 
strains. This finding might explain the small (~20%) relative increase in the amount of 
adenosine A1 receptors in hypertensive mesenteric arteries, suggesting a neuron-to-glia 
redistribution of adenosine A1 receptors in hypertensive arteries. To our knowledge, this is 
also the first time where distribution/redistribution of adenosine A1 or A2A receptors 
between neurons and Schwann cells in hypertensive arteries has been reported. Changes in 
the localization of adenosine receptors and the increased amount of extracellular adenosine 
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observed in SHR mesenteric arteries suggest that receptor desensitization may be the main 
reason for adenosine receptor activity impairment observed in hypertensive arteries. 
Indeed, the lack of tonic adenosine A1 receptor-mediated inhibition in these arteries may 
contribute to increase noradrenaline release from stimulated sympathetic nerves. This 
provides a convincing explanation for the dominance of noradrenaline as neurotransmitter 
in hypertensive rats.[35] Accordingly, decreases in adenosine A1 receptor-mediated 
inhibitory tonus may cause a profound impact in vascular reactivity, contributing to 
hypertension. Moreover, the amount of ATP released from sympathetic nerves was higher 
in SHR than in WKY mesenteric arteries which correlates well with a previous work where 
an enhanced purinergic function was described, revealing ATP as a vasoconstrictor in SHR 
arteries.[2]  
 
 
CONCLUSIONS 
 
Results from this work highlight the role of purines in hypertension. Data showed 
that the increase in sympathetic activity in hypertensive arteries may be partially due to an 
higher ATP release from sympathetic postganglionic nerves and the lack of endogenous 
adenosine inhibitory tonus. The latter might be explained by the nerve-to-glial 
redistribution of inhibitory adenosine A1 receptors found to occur in hypertensive arteries. 
These mechanisms would lead to an increase in noradrenaline and ATP release from 
stimulated sympathetic nerves. Taken this into account one can predict that, in the synaptic 
cleft, in addition to higher levels of noradrenaline, increased amounts of ATP are likely to 
accumulate with subsequent vasoconstriction of vascular smooth muscle cells by α1 
adrenoceptors and P2 receptors activation, respectively. Such changes may have impact in 
vascular reactivity, contributing to hypertension, renewing the interest of the purinergic 
system as a target for novel therapeutic strategies.  
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ABSTRACT 
 
Objectives 
The present study intends to clarify if endothelium dysfunction impairs vascular 
sympathetic neurotransmission.  
 
Methods 
Electrically-evoked tritium overflow (100 pulses/5 Hz) was evaluated in arteries (intact and 
denuded) or exhibiting some degree of endothelium dysfunction (spontaneously 
hypertensive arteries), pre-incubated with [3H]-noradrenaline in the presence of enzymes 
(nitric oxide synthase (NOS); nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase; xanthine oxidase; cyclooxygenase; adenosine kinase) inhibitors and a nucleoside 
transporter inhibitor.  
 
Results  
Inhibition of endothelial nitric oxide synthase with L-NIO dihydrochloride reduced tritium 
overflow in intact arteries whereas inhibition of neuronal nitric oxide synthase with Nω-
Propyl-L-arginine hydrochloride was devoid of effect showing that only endothelial nitric 
oxide synthase is involved in vascular sympathetic neuromodulation. Inhibition of enzymes 
involved in reactive oxygen species or prostaglandins production with apocynin and 
allopurinol or indomethacin, respectively, failed to alter tritium overflow. A facilitation or 
reduction of tritium overflow was observed in the presence of 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX) or of 5-iodotubericidin, respectively, but only in intact arteries. 
These effects can be ascribed to a tonic inhibitory effect mediated by A1 receptors. In 
denuded and hypertensive arteries, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-
e]-1,2,4-triazolo[1,5-c] pyrimidine (SCH 58261) reduced tritium overflow, suggesting the 
occurrence of a tonic activation of A2A receptors. When endogenous adenosine 
bioavailability was increased by the nucleoside transporter inhibitor, S-(4-Nitrobenzyl)-6-
thioinosine, tritium overflow increased in intact, denuded and hypertensive arteries.  
 
Conclusions 
Among the endothelium-derived substances studied that could alter vascular sympathetic 
transmission only adenosine/adenosine receptor mediated mechanisms were clearly 
impaired by endothelium injury/dysfunction.  
 
 
Keywords: endothelium dysfunction, nitric oxide, adenosine, noradrenaline, SHR. 
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INTRODUCTION 
 
It is well established that blood vessel tone can be modulated by the release of 
various endothelium-derived endogenous substances1 namely contracting  (endothelin, 
prostaglandin F2a and thromboxane A2) and/or relaxing (prostaglandin I2 and nitric oxide, 
NO) factors.[2, 3] These substances can modify vascular smooth muscle tone directly, acting 
on smooth muscle cells, or indirectly, by altering sympathetic transmission.[4] Such 
regulation can be impaired if integrity and/or function of endothelium is compromised. 
Increasing evidence suggest that endothelial dysfunction, with altered NO production and 
oxidative stress, may contribute to the pathogenesis of hypertension driving to increased 
peripheral vascular resistance, as endothelium removal and endothelium dysfunction 
resulted in the enhancement of contractile responses to vasoconstrictor agents.[5-9]  
Moreover, several studies revealed that endothelial cells may be dynamically involved in the 
vascular response to receptor stimulation,[5] namely α- or β-adrenoceptors[10] or 
adenosine receptors.[11-14] 
In addition, some studies reported that endothelium may alter sympathetic 
transmission, known to be implicated in cardiovascular diseases. This is true for central 
noradrenergic neurons associated with cardiovascular control[15] and also for the 
peripheral sympathetic innervation of vessels.[16] However, to our knowledge, the role of 
endothelium dysfunction in sympathetic transmission has never been studied, although 
some studies had shown that endothelium might influence the levels of noradrenaline 
released from sympathetic terminals.[11] 
The present investigation was designed to address the hypothesis that endothelium 
dysfunction alters vascular sympathetic neurotransmission and contributes to increase 
vascular tone and, consequently, blood pressure. To achieve this goal, we have investigated, 
in intact and denuded arteries, the modulatory roles exerted by i) endogenous NO, 
generated by endothelial NOS (eNOS) and neuronal NOS (nNOS); ii) oxidative stress, 
through evaluation of enzymes involved in reactive oxygen species production such as 
NADPH oxidase and xanthine oxidase; iii) prostaglandins production, through 
cyclooxygenase activity and iv) endogenous adenosine via activation of adenosine A1 or A2A 
receptor subtypes, in the sympathetic vascular neurotransmission. We have also evaluated 
if these pathways are compromised in tail arteries from spontaneously hypertensive rats, an 
animal model exhibiting endothelium dysfunction.[17, 18] 
 
 
 
 
Adenosine receptors in vascular sympathetic neurotransmission: the role of endothelium and of nitric oxide-
mediated effects and their relation with hypertension 
78 
 
MATERIALS AND METHODS 
 
Chemicals 
 
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 
41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); desipramine 
hydrochloride, Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME), Indomethacin 
(cyclooxygenase (COX) inhibitor), Allopurinol, 8-Cyclopentyl-1,3-dipropylxanthine 
(DPCPX), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c] 
pyrimidine (SCH 58261), S-(4-Nitrobenzyl)-6-thioinosine (NBTI), 5-Iodotubericidin (ITU) 
and saponin  were purchased from Sigma-Aldrich (Sintra, Portugal); Nω-Propyl-L-arginine 
hydrochloride, L-NIO dihydrochloride and Apocynin (NADPH oxidase inhibitor) were 
purchased from TOCRIS Bioscience. 
All other reagents were of analytical grade. Stock solutions were made up in 
dimethylsulphoxide (DMSO: 0.01% v/v, final concentration) or ultrapure water and diluted 
in superfusion medium immediately before use. DMSO was added to the superfusion 
medium (final concentration 0.01%), in parallel control experiments.   
 
Animals 
 
Adult male Wistar Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) (12 
weeks old, 270-350 g) purchased from Charles River (Barcelona, Spain) were used. Animals 
were kept under light/dark cycles of 12/12 h, 20-22ºC, and had free access to water and 
pellet food. Handling and care of animals were conducted according to the guidelines from 
Directive 2010/63/EU of the European Parliament on the protection of animals used for 
scientific purposes; (in agreement with the NIH guidelines) and granted by the Faculty of 
Pharmacy of University of Porto Ethics Committee. In accordance with good practice, in 
studies involving the response of the sympathetic nervous system, the use of anesthetics is 
inadvisable once it may compromise the validity and reproducibility of results. Thus, the 
animals are sacrificed using a guillotine, the method being reported as the sacrificial 
advisable in studies involving the nervous system. The tissue samples were collected 
immediately after sacrifice. Two animals per experiment were used and tail arteries were 
dissected. Seven tissue preparations (5 to 9 mg) were obtained from each artery.  
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Experimental Protocol 
 
[3H]-Noradrenaline release experiments 
 
The protocol used to label tissue preparations with [3H]-noradrenaline and to 
evaluate changes on electrically-evoked tritium overflow was performed according to 
previous studies.[19-23] Briefly, tail arteries were dissected and, for experiments with 
denuded preparations, endothelium was mechanically removed with a thin stainless steel 
wire. In a set of experiments endothelium was chemically removed using saponin (0.1 
mg/ml). After dissection, arteries were immediately placed in cold Krebs-Henseleit solution 
of the following composition (in mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, NaH2PO4 
1.2, NaHCO3 25, glucose 11, ascorbic acid 0.3 and disodium EDTA 0.03 (pH 7.4).  
Arteries were then incubated in 2 ml Krebs-Henseleit solution containing 0.1 M 
[3H]-noradrenaline (for 60 min at 37ºC) and transferred into superfusion chambers, 
superfused with [3H]-noradrenaline-free medium (1ml.min-1; constant rate: Krebs-
Henseleit solution with desipramine 400 nM to inhibit noradrenaline’s neuronal uptake). 
Up to three periods of electrical stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo Sachs 
Elektronik, March-Hugstetten, Germany) were applied: the first stimulation period, t = 45 
min (S0), served to test the viability of the preparation and medium was not collected during 
this period; the subsequent two stimulation periods (S1 and S2) were applied with 30 min 
intervals (t=90 min and t=120 min, respectively). The superfusate was collected in 5 min 
periods from 85 min of superfusion onwards (t=0 min being the onset of superfusion). At 
the end of the experiments (t=130 min), tritium was measured in superfusate samples and 
solubilized arteries (sonicated 1h with 2.5 ml perchloric acid (0.2 M)) by liquid scintillation 
spectrometry (LS 6500, Beckman Instruments, Fullerton, USA) after adding 6 ml of 
scintillation mixture (OptiPhase ‘Hisafe’ 3, PerkinElmer, I.L.C., Lisboa, Portugal) to each 
sample.  
From each animal, no more than three tissue preparations were submitted to 
identical treatments. Effects of antagonists (DPCPX and SCH 58261), and of several enzyme 
inhibitors (L-NAME, Nω-Propyl-L-arginine hydrochloride and L-NIO dihydrochloride, 
ITU, Apocynin, Indomethacin and Allopurinol) on NA release (estimated as tritium 
overflow) were studied.  
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ε-adenosine assay in artery superfusates 
 
1,N6-Etheno (ε)-modified purines (adenine nucleotides and adenosine) have been 
previously prepared with collected samples from tissue superfusates by several authors.[24-
26] Briefly, tail artery segments were transferred into superfusion chambers, superfused at 
a constant rate of 1ml.min-1 with Krebs-Henseleit solution. Up to three periods of electrical 
stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo Sachs Elektronik, March-Hugstetten, 
Germany) were applied: the first stimulation period, t = 45 min (S0), served to test the 
viability of the preparation and the medium was not collected during this period; the 
subsequent two stimulation periods (S1 and S2) were applied with 30 min intervals (t=90 
min and t=120 min, respectively). The superfusate was collected in 5 min periods before 
and after stimulation and each sample was then heated at 80ºC (to denature enzymes that 
might be co-released). The collected samples (910 µl) were then incubated with 
chloroacetaldyde (90 µl) for 50 min at 70ºC in a dry bath incubator (Heraeus Instruments, 
Hanau, Germany). Reactions were stopped by placing samples on ice. Identification of the 
ε-adenosine formed in this collected samples was confirmed by HPLC using a fluorescent 
detector (model LS20; Perkin Elmer, Beconsfield, UK) at 230 nm excitation and 420 nm 
emission wavelengths. The stationary phase was 5 µm particle size packed in a 25 cm long 
by 4 mm internal diameter ODS- (C18) column and matching 1 cm long by 3.3 mm diameter 
direct-connect guard column (ACE-Advanced Chromatography technology, Aberdeen, 
Scotland) in a gradient HPLC system (306 and 811C Gilson, Gilson Medical Electronics, 
Middleton, WI, USA). The column was kept at room temperature (20-22ºC). The mobile 
phase consisted of a solution of 87 mM KH2PO4 and 10.6 mM Na2HPO4 (pH 6.0) as buffer 
A; buffer B was made up 25% methanol and 75% buffer A. Gradient elution was used 
according to the following linear program: from 0 to 20 min of elution, a convex gradient 
from 0 % to 100% of Buffer B at a flow rate of 1ml/min; from 0 to 3 min of elution, an 
increase from 0% to 25% of buffer B at a flow rate of 1ml/min; from 3 to 7 min of elution, 
25% of buffer B at a flow rate of 1ml/min; and from 8 to 12 min of elution an increase from 
25% to 100% of buffer B at a flow rate of 1ml/min; from 12 to 20 min of elution, 100% of 
buffer B at a flow rate of 1ml/min. The run time of 20 min and the post-run time was 5 min.  
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Data analysis 
 
[3H]-Noradrenaline release experiments 
 
Evaluation of [3H]-noradrenaline release experiments were carried out as previously 
described. Briefly, effects of drugs added after S1 on electrically-evoked tritium overflow 
were evaluated as ratios of the overflow elicited by S2 and the overflow elicited by S1 (S2/S1). 
S2/S1 ratios obtained in individual experiments in which a test compound A was added after 
S1 were calculated as a percentage of the appropriate control group (solvent instead of A). 
 
Quantification of the ε-adenosine formed in collected artery superfusates 
 
The amount of adenosine (pmol/mg of tissue) in each collected sample was 
estimated from calibration curves of adenosine standards, derivatized as described, run 
with every set of 20 samples.  
 
Statistics 
 
Results are expressed as mean±s.e.m. and n denotes the number of tissue 
preparations. Differences of means were compared for significance using one- or two-way 
ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t test. A P value less than 
0.05 was considered to denote statistically significant differences.  
 
 
 
RESULTS 
 
Noradrenaline release from tail sympathetic nerve terminals  
 
Electrically-evoked tritium overflow from tissue preparations incubated with [3H]-
noradrenaline has been shown to reflect action potential-evoked neuronal noradrenaline 
release and drug-induced changes in evoked tritium overflow can be assumed to reflect 
changes in neuronal noradrenaline release, as observed in previous studies.[19-23]  
The outflow of tritium was markedly increased in tail arteries, pre-incubated with 
[3H]-noradrenaline, when stimulated with 100 pulses/5 Hz (Figure 1).  
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Figure 1. Time course of tritium outflow from: (A) intact (filled circles) and denuded (open circles); 
(B) SHR (triangles) and WKY (circles) tail artery segments from typical experiments. After pre-
incubation with [3H]-noradrenaline, tissues were superfused with [3H]-noradrenaline free medium 
containing desipramine (400 nM). Tritium outflow (ordinates) is expressed as a percentage of the 
total radioactivity present in the tissue at the beginning of the collection period and was measured in 
samples collected every 5 min. Artery segments were stimulated twice by 100 pulses/5 Hz, (S1, S2). 
Each line represents the outflow of tritium from a single superfusion chamber. 
 
 
 
 The fractional rate of efflux immediately before S1 (b1) and electrically-evoked 
tritium overflow (S1), in the absence of drugs other than desipramine (400 nM), are shown 
in Table 1.  
In the present study, endothelium integrity was compromised by mechanical 
removal or chemical injury (that induces degenerative changes in the endothelial cells).[27] 
Nevertheless, b1 and S1 values obtained using the two different procedures were 
similar; therefore further experiments were carried out with mechanical removal of 
endothelium. Endothelium (mechanical or chemically compromised) did not modify the 
basal outflow (b1) but increased the electrically-evoked tritium overflow (S1) (Table 1). In 
tail arteries from SHR, the basal outflow (b1) was smaller than those observed in WKY 
arteries and S1 values were intermediate between those of intact and denuded arteries 
(Table 1; Figure 1). In control conditions, basal outflow and electrically-evoked tritium 
overflow remained constant throughout experiments, with bn/b1 and Sn/S1 average values 
close to unity (data not shown). 
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Table 1. Basal tritium outflow (b1), electrically-evoked tritium overflow (S1) 
and S2/S1ratios from WKY and SHR segments of tail artery 
       Basal Outflow (b1)         Evoked Overflow (S1)        n 
       (fractional rate of               (% of tissue tritium 
         outflow; min-1)                     content) 
WKY endothelium 
Intact                             0.095±0.004         0.185±0.014       20 
Mechanically removed  0.077±0.003*        0.278±0.013*       16 
Chemically removed                0.071±0.013*       0.264±0.025*         5 
SHR endothelium 
Intact               0.060±0.004*           0.250±0.016*       15 
Tail artery segments were pre-incubated with [3H]-noradrenaline for 40 min. After pre-incubation 
with [3H]-noradrenaline, arteries were superfused with [3H]-noradrenaline free medium containing 
desipramine (400 nM). Arteries were stimulated twice at 30-min intervals (S1-S2; 100 pulses, 5 Hz, 1 
ms, 50 mA): b1 refers to the 5-min period immediately before S1. The electrically-evoked tritium 
overflow was calculated by subtracting the estimated basal outflow from total outflow observed 
during and in the 25-min period subsequent to S1 and expressed as a percentage of the tissue tritium 
content at the onset of stimulation. Values presented are means±SEM and n denotes the number of 
artery segments. Significant differences from WKY intact endothelium: *P<0.05 (one-way ANOVA 
followed by post-hoc Holm-Sidak’s multicomparisons t-test) 
 
 
 
Influence of endothelium upon vascular sympathetic neurotransmission 
 
Sympathetic transmission can be altered by substances produced in endothelial 
cells, such as NO,[28, 29] reactive and/or nitrogen oxygen species (ROS and/or RNS), 
prostaglandins.[30, 31] 
NO was documented as having influence on vascular reactivity namely by altering 
contractions elicited by electrical field stimulation.[32] To evaluate the role of NO in 
vascular sympathetic neurotransmission, a set of experiments was carried out using NOS 
inhibitors: L-NAME, a non-specific NOS inhibitor (100 µM), Nω-Propyl-L-arginine 
hydrochloride, a specific neuronal NOS (nNOS) inhibitor (100 nM) and L-NIO 
dihydrochloride a specific endothelial NOS (eNOS) inhibitor (500 nM). Results shown in 
Figure 2 revealed that, in intact tail arteries, both L-NAME and L-NIO dihydrochloride were 
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unable to inhibit tritium release in 27 and 35%, respectively, while Nω-Propyl-L-arginine 
hydrochloride was ineffective to modify it. In denuded arteries all tested compounds failed 
to change tritium overflow. Taken together, these data suggests that nNOS is not 
contributing to alter sympathetic transmission in tail arteries. In SHR arteries, all NOS 
inhibitors used were devoid of effect. 
 
 
 
Figure 2. Influence of NOS inhibitors on vascular sympathetic transmission in: (A) WKY intact and 
denuded and (B) SHR tail arteries. Interaction with L-NAME, a non-selective NOS inhibitor (100 
µM), Nω-Propyl-L-arginine hydrochloride, a specific neuronal NOS (nNOS) inhibitor (INOSn: 100 
nM) and L-NIO dihydrochloride, a specific endothelial NOS (eNOS) inhibitor (INOSe: 500 nM), on 
the electrically-evoked tritium overflow. Tissues were electrically stimulated (S1-S2: 100 pulses/5 Hz). 
Drugs were added immediately after S1 and kept until the end of the experiment. Ordinates: S2/S1 
values obtained in individual artery segments, expressed as a percentage of the appropriate S2/S1 
control value. Values are mean±s.e.m. from 4 to 15 artery segments (5 WKY and 3 SHR). Significant 
differences from the appropriate control: *P<0.05, **P<0.001; from denuded arteries: #P<0.05 (two-
way ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t-test) 
 
 
An increase in NO availability has been linked with an increase in intracellular 
calcium levels.[33] In intact arteries, the calcium ionophore A23187 (100 nM), described to 
promote a massive increase in intracellular calcium levels, failed to change noradrenaline 
release (1.10±0.13; n=4; P>0.05). 
Oxidative stress may generate ROS that can alter NO-mediated effects, by altering 
NO bioavailability.[34] Therefore, we tested the effects, on the electrically-evoked tritium 
overflow, elicited by inhibitors of enzymes involved in the formation of ROS. Vascular 
NADPH oxidase, an important source of vascular radical formation,[35] was inhibited using 
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apocynin (10 µM) and xanthine oxidase, an enzyme with particularly high expression in 
vascular endothelium, known as a source of ROS,[36] was inhibited using allopurinol (10 
µM). These inhibitors were unable to modify tritium release in intact, denuded and SHR tail 
arteries (Figure 3).  
In the endothelium, prostaglandins are generated after cyclooxygenase (type I and 
II) activation, and were described to influence sympathetic transmission[37] through the 
activation of different pathways, some of them involving NO-mediated effects.[38] To 
challenge this possibility, indomethacin, a non-selective cyclooxygenase inhibitor, was 
used. Indomethacin failed to change tritium overflow in intact, denuded and SHR tail 
arteries (Figure 3).  
 
 
 
Figure 3. Prostaglandins and ROS involvement on vascular sympathetic transmission in: (A) WKY 
intact and denuded and (B) SHR tail arteries. Effects of indomethacin (10 µM, non-selective COX 
inhibitor), apocynin (10 µM, NADPH oxidase inhibitor) and allopurinol (10 µM, xanthine oxidase 
inhibitor) on the electrically-evoked tritium overflow. Tissues were electrically stimulated (S1-S2: 100 
pulses/5 Hz). Drugs were added immediately after S1 and kept until the end of the experiment. 
Ordinates: S2/S1 values obtained in individual artery segments, expressed as a percentage of the 
appropriate S2/S1 control value. Values are mean±s.e.m. from 5 to 14 artery segments (5 WKY and 3 
SHR). Non-Significant differences from the appropriate control were found (two-way or one-way 
ANOVA). 
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Role of endogenous adenosine upon vascular sympathetic transmission 
 
An ubiquitous mediator described to be involved in neurotransmission both in 
central and peripheral nervous system is adenosine.[39, 40] To evaluate if endogenous 
adenosine is modulating vascular noradrenaline release pathways, selective antagonists for 
A1 and A2A receptors, DPCPX (100 nM) and SCH 58261 (20 nM) were used (Figure 4). In 
the presence of DPCPX, a facilitation (up to 20%) occurred, compatible with a tonic 
inhibitory effect mediated by A1 receptors observed only in intact arteries. By opposition, 
SCH 58261 revealed an inhibition that is, most likely, due to a tonic effect mediated by A2A 
receptors but only in denuded (up to -35%) and hypertensive (up to 20%) arteries (with 
endothelium integrity compromised). To evaluate the impact of endogenous adenosine 
increase on neurotransmission dynamics, ITU (100 nM), an adenosine kinase inhibitor that 
prevents the phosphorylation of adenosine into AMP, was used. An inhibition of tritium 
release was observed in intact tissues while in endothelium free tissues (denuded arteries); 
a facilitation of tritium release was observed (Figure 4). These effects correlate well with 
data obtained in the presence of DPCPX and SCH in intact and denuded arteries, 
respectively (Figure 4).  
These findings suggest that adenosine availability may be higher in denuded arteries 
comparatively to intact ones. In endothelium dysfunctional arteries (SHR arteries) 
however, noradrenaline release was not altered by ITU treatment, probably because there 
is already a constitutively higher amount of adenosine in hypertensive/endothelium 
dysfunctional arteries.  Since transmitters release modulation ascribed to extracellular 
adenosine availability depends not only on its formation but also on its cellular uptake (by 
nucleoside transporters), experiments were carried out in the presence of NBTI (a 
nucleoside transporter inhibitor, 5 µM) that facilitated tritium overflow in all artery 
preparations (intact, denuded and SHR). However, facilitation was more pronounced in 
intact arteries. This difference can be related to the facilitation induced by NO, as shown in 
Figure 2, and confirmed by experiments where intact arteries were treated with NBTI plus 
L-NAME  that showed increased levels of noradrenaline release (149.8±12.8; n=5) similar 
to those observed in denuded arteries (150.3±4.7; n=5). 
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Figure 4. Influence of endogenous adenosine on vascular sympathetic transmission in: (A) WKY 
intact and denuded and (B) SHR tail arteries. Interaction with selective adenosine receptor 
antagonists DPCPX (100 nM; A1 subtype antagonist), SCH 58261 (20 nM; A2A subtype antagonist) 
and ITU (100 nM adenosine kinase inhibitor) and/or NBTI (5 µM; a nucleoside transporter inhibitor) 
on the electrically-evoked tritium overflow. Tissues were electrically stimulated (S1-S2: 100 pulses/5 
Hz). Drugs were added immediately after S1 and kept until the end of the experiment. Ordinates: 
S2/S1 values obtained in individual artery segments, expressed as a percentage of the appropriate 
S2/S1 control value. Values are mean±s.e.m. from 5 to 15 artery segments (7 WKY and 4 SHR). 
Significant differences from the appropriate control: *P<0.05, **P<0.001; from denuded arteries: 
##P<0.001; from WKY arteries: †P<0.05; ††P<0.001 (two-way ANOVA followed by post-hoc Holm-
Sidak’s multicomparisons t-test). 
 
 
Adenosine levels in WKY and SHR tail arteries 
 
Extracellular adenosine can either be released as such, via nucleoside transporters, 
or produced from extracellular catabolism of released adenine nucleotides, namely ATP, 
from distinct cells including neurons.[41] ATP is then sequentially dephosphorylated into 
ADP, AMP and adenosine. Endogenous levels of adenosine were significantly higher in 
superfusates from SHR tail arteries, comparatively to those of WKY (Figure 5), both under 
basal conditions and after stimulation (5 Hz/100 pulses). Surprisingly, adenosine levels, 
before and after stimulation, were similar in both strains. 
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Figure 5. Basal and electrically-evoked adenosine release from tail arteries of WKY and SHR. Tissues 
were electrically stimulated (S1-S2: 100 pulses/5 Hz). Values are mean±s.e.m. from 8-10 artery 
segments (3 WKY and 3 SHR). Significant differences from WKY arteries: # P<0.05 (one-way ANOVA 
followed by post-hoc Holm-Sidak’s multicomparisons t-test). 
 
 
 
DISCUSSION 
 
In the present study endothelium was removed (mechanical or chemically) from tail 
arteries to mimic endothelium injury/dysfunction, and this strategy was found to induce an 
increase in noradrenaline release from vascular sympathetic nerves. This observation is in 
line with previous reports that described endothelium dependent effects in vascular 
responsiveness, including sympathetic transmission.[2, 10-14] Nevertheless, data revealed, 
for the first time, that this increase of noradrenaline release is still occurring in vessels 
exhibiting endothelial dysfunction (SHR tail arteries). Surprisingly, endothelium-derived 
substances such as ROS and prostaglandins, did not alter the neuromodulatory 
mechanisms, whereas adenosine-mediated effects in vascular neurotransmission were 
clearly impaired by endothelium injury/dysfunction.  
The increase in sympathetic transmission (elicited by endothelial dysfunction) 
observed can not be explained by an increase in oxidative stress, since NADPH oxidase 
and/or xanthine oxidase inhibitors did not alter noradrenaline release levels. Therefore, 
ROS can be discarded as i) a putative effector in this imbalance, contrary to ROS-mediated 
effects in other vascular physiological functions[42] or as ii) being involved in NO 
inactivation in arteries which would decrease NO bioavailability.[43-45] NO bioavailability 
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is also a consequence of its production status and might influence NO-mediated effects, 
including those related to sympathetic transmission. Indeed, NO production was found to 
increase noradrenaline release but only in intact arteries which can be explained by the 
interplay of NO with the adrenergic system pathway, namely with facilitatory β-
adrenoceptors, as previously described.[46, 47] In intact arteries, the non-selective NOS (L-
NAME) and eNOS inhibitors, inhibited noradrenaline release whereas nNOS inhibitor did 
not alter noradrenaline release. In denuded and SHR arteries, however, all NOS inhibitors 
failed to alter sympathetic transmission and, as such, NO cannot be considered the key 
element involved in altering sympathetic transmission when integrity of endothelium is 
compromised. It has been proposed, in previous studies, that NO did not alter sympathetic 
neurotransmission in tail arteries,[48] which is in line with the absence of nNOS activity 
observed in the present study. However, our data clearly showed an eNOS-mediated effect 
in sympathetic transmission, which represents, to our knowledge, a new role for eNOS in 
vessels. 
It has been previously described that adenosine A1 and A2A receptor activation in 
endothelial cells lead to an increase in intracellular Ca2+, a middle step pathway in the 
cascade of events  that, consequently, triggers eNOS.[33] As we have observed that 
adenosine and NO are most likely operating independently to influence noradrenaline 
release and since alteration in intracellular calcium levels was devoid of effect, the interplay 
between signaling cascades involving these signaling mediators in the modulation of 
sympathetic neurotransmission can be discarded. Moreover, indomethacin was also devoid 
of effects reinforcing the idea that the signaling pathway triggered by endothelial A1 
receptors activation that would lead to activation of K+ATP channels-PLA2-COX-PGI2-PKA-
NOS pathway[33] is not involved in the modulation of noradrenaline release in tail arteries. 
These observations indicate, therefore, that the high affinity adenosine receptor subtypes, 
A1 and A2A, are most likely located in presynaptic terminals and not in endothelial cells. In 
this regard, adenosine A1 and A2A receptors are distinctly involved in neurotransmission 
modulation when endothelium integrity is altered: in denuded endogenous adenosine is 
tonically activating A2A receptors (causing a marked increase in sympathetic activity 
comparatively to the activity observed in intact arteries), an effect that is still observed, with 
similar magnitude, in SHR arteries. An additional contribution to the increased sympathetic 
activity observed in these tissues can be ascribed to the absence of inhibitory A1 receptor-
mediated effects (in both denuded and SHR arteries). These data strongly contrast with 
results obtained in intact arteries where modulation of noradrenaline release by 
endogenous adenosine involves inhibitory but not facilitatory adenosine receptors (see 
Figure 4). Since adenosine A2A receptors require concentrations two-fold higher than those 
needed to activate adenosine A1 receptors[49] endogenous adenosine availability seems to 
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be crucial to discriminate the subtype of adenosine receptor that is activated. Therefore, the 
sympathetic activity impairment observed in arteries exhibiting some degree of 
endothelium dysfunction can be ascribed to alterations in the dynamics of the adenosinergic 
system. Adenosine receptors, nucleoside transporters and adenosine availability are known 
to be the key effectors in adenosinergic system dynamics and any change in one of these 
items may cause profound impact in the function of the others.[50] 
When adenosine bioavailability increased by inhibiting adenosine kinase (by ITU) a 
dual effect was observed, depending on artery endothelium integrity state: in intact arteries 
an inhibition of noradrenaline release was observed while in arteries where endothelium 
was removed a facilitation of noradrenaline occurred (Figure 4). In SHR arteries, ITU did 
not alter noradrenaline release, which it is conceivable to happen if there is already a 
constitutively higher amount of adenosine in hypertensive/endothelium dysfunctional 
arteries (Figure 5). Therefore, although ITU could increase even more adenosine levels, this 
increase was unable to potentiate further A2A activation (that is likely already in its 
maximum activity state). Since these effects are due to a tonic activation of adenosine 
receptors subtypes (A1 and A2A), a possible nucleoside transport dynamic change can be 
behind the increased availability of adenosine observed in SHR arteries. 
Blockade of nucleoside transport (by NBTI) caused facilitation of noradrenaline 
release in intact, denuded and SHR arteries due to the increase in extracellular adenosine 
levels, able to activate facilitatory A2A receptors.  
An additional source of adenosine could be attributable to electrically-evoked ATP 
release from sympathetic neurons however the amount of adenosine observed before and 
after stimulation was similar, in SHR arteries, challenging this possibility.   
Taken together, the facilitatory effects observed in the presence of ITU and NBTI in 
denuded arteries suggest that the main mechanism that regulates adenosine extracellular 
levels involves nucleoside uptake to endothelial cells. Thus, when endothelium is somehow 
compromised this transport seems to be deregulated causing accumulation of extracellular 
adenosine.  
In conclusion, the present study revealed, for the first time, that endothelium 
dysfunction causes an increase in sympathetic neurotransmission constituting, an 
additional aggravating factor in pathologies secondary to hypertension or hypertension 
itself. Surprisingly, the involvement of endothelium-derived substances (ROS and 
prostaglandins) in mechanisms leading to altered neuromodulation was ruled out, whereas 
adenosine-mediated neuromodulatory mechanisms were clearly impaired by endothelium 
injury/dysfunction.  
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ABSTRACT  
 
Conflicting data suggests that NO may influence noradrenaline release from 
vascular postganglionic sympathetic nerves. Some studies indicate that NO promote an 
inhibition while others indicate the involvement of NO in the facilitation of noradrenaline 
release. We aim at investigating the role of NO in vascular sympathetic neurotransmission 
in the mesenteric and tail arteries. The influence of NO on noradrenaline release was found 
to be distinct between mesenteric and tail arteries with a pronounced enhancement of 
noradrenaline release caused by NO mediated activation in intact tail arteries: DEA 
NONOate (10 µM), a NO donor, facilitated tritium overflow up to 18,80±0.10% or by the 
inhibition (up to -25,79±0,045% obtained in the presence of L-NAME (100 µM), a NO 
synthase inhibitor. In denuded arteries L-Name (100 µM) failed to modify noradrenaline 
release. DEA NONOate (10 µM) and SNP (100 µM), two different NO donors caused 
inhibition of noradrenaline release in denuded arteries, -18,92±0,15% and -24,42±0,061%, 
respectively. Data indicate that the signalling pathway activated by exogenous NO, 
ultimately causes a reduction in noradrenaline release in denuded tail arteries, in opposition 
to the effects observed in intact tail arteries. Endogenous NO, produced most probably in 
the endothelium, in turn, mediate an enhancement of noradrenaline release. These indicate 
that NO from different sources can induce opposite effects probably through 
activation/influence of distinct pathways. 
Keywords: Endothelium, nitric oxide, vascular sympathetic nerves, noradrenaline. 
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INTRODUCTION  
 
Endothelium is an important regulator of vascular tonus via release of various 
endothelium-derived substances[1] such as nitric oxide (NO).[2] Several studies have 
reported that endothelium may decrease noradrenaline release from vascular 
postganglionic sympathetic nerves [rabbit and canine vessels: 3, 4, 5] and neurogenic 
vasoconstriction [rabbit carotid artery: 6]. However, there is no consensus in the literature 
regarding the modulatory role of NO on vascular sympathetic reactivity:  it has been 
described that an inhibitor of NO production did not modify noradrenaline release [dog 
temporal artery: 7] but rather caused a reduction in adrenaline release in vivo [rabbit: 8, 9]. 
The source of the NO involved in this putative modulatory mechanism is still unknown: 
some studies ascribe to exogenous NO a reduction in neurotransmitter release [frog 
neuromuscular junction: 10] while others have reported the involvement of endogenous NO 
in sympathetic vasoconstriction [rat: 11].  
The aim of the present work was to study whether or not NO (from endothelial or 
extra-endothelial origin) is able to modify noradrenaline release from vascular 
postganglionic sympathetic nerve endings in a vascular bed, the isolated ventral rat tail 
artery.   
 
 
METHODS 
 
Chemicals 
 
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 
41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); desipramine 
hydrochloride, sodium nitroprusside, L-Arginine and Nω-Nitro-L-arginine methyl ester 
hydrochloride were purchased from Sigma-Aldrich (Sintra, Portugal). DEA-NONOate was 
purchased from MERCK Milipore. Stock solutions were made up in dimethylsulphoxide 
(DMSO: 0.01% v/v, final concentration) or ultrapure water and diluted in superfusion 
medium immediately before use. DMSO was added to the superfusion medium (final 
concentration 0.01%), in parallel control experiments. 
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Animals 
 
Adult male Wistar rats (270-360 g; Charles River, Barcelona, Spain) were used. 
Animals were kept under light/dark cycles of 12/12 h, 20-22ºC, and free access to water and 
pellet food. Handling and care of animals were conducted according to the European Union 
guidelines for animal research (86/609/EEC; in agreement with the NIH guidelines) and 
Portuguese law (Portarias nº1005/92 and nº1131/97). Animals were killed by stunning 
followed by exsanguination. Two animals per experiment were used and the 
mesenteric/caudal (endothelium intact or denuded) arteries were dissected out. 
Endothelium was removed by gentle rubbing of the inner lumen with a stainless steel wire. 
Five to six tissue preparations (5 to 9 mg) were obtained from each artery. 
 
 
[3H]-Noradrenaline release experiments 
 
After dissection, arteries were immediately placed in cold Krebs-Henseleit solution of 
the following composition (in mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, NaH2PO4 1.2, 
NaHCO3 25, glucose 11, ascorbic acid 0.3 and dissodium EDTA 0.03 (pH 7.4). The protocol 
used to label tissue preparations with [3H]-noradrenaline and to evaluate changes on 
electrically-evoked tritium overflow was performed according to previous studies [12, 13, 
14, 15], with minor modifications. Briefly, arteries were pre-incubated in 2 ml Krebs-
Henseleit solution containing 0.1 µM [3H]-noradrenaline (for 40 min at 37ºC) and 
transferred into superfusion chambers, superfused with [3H]-noradrenaline-free medium 
(1ml min-1; constant rate: Krebs-Henseleit solution with desipramine 400 nM to inhibit 
noradrenaline’s neuronal uptake). Up to three periods of electrical stimulation (5 Hz, 100 
pulses, 1 ms, 50 mA; Hugo Sachs Elektronik, March-Hugstetten, Germany) were applied: 
the first stimulation period, t = 45 min (S0), served to test the viability of the preparation 
and medium was not collected during this period; the subsequent two stimulation periods 
(S1 to S2), started at t=90 min, were applied with 20 min intervals. The superfusate was 
collected in 5 min periods from 85 min of superfusion onwards (t=0 min being the onset of 
superfusion). At the end of the experiments (t=130 min), tritium was measured in 
superfusate samples and solubilized arteries and veins by liquid scintillation spectrometry 
(LS 6500, Beckman Instruments, Fullerton, USA) after adding 6 ml of scintillation mixture 
(OptiPhase ‘Hisafe’ 3, PerkinElmer, I.L.C., Lisboa, Portugal) to each superfusate sample. At 
the end of experiments 2.5 ml perchloric acid (0.2 M) were added to each tissue and these 
flasks were sonicated for 1h. After tissue removal, 6 ml of scintillation mixture were also 
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added. From each animal, no more than two tissue preparations were submitted to identical 
treatments. 
 
 
Data analysis 
 
Evaluation of [3H]-noradrenaline release experiments was carried out as previously 
described.[12, 13, 14, 15] Briefly, effects of drugs added after S1 on electrically-evoked tritium 
overflow were evaluated as ratios of the overflow elicited by Sn and the overflow elicited by 
S1 (Sn/S1). Sn/S1 ratios obtained in individual experiments in which a test compound A was 
added after S1 were calculated as a percentage of the respective mean ratio in the 
appropriate control group (solvent instead of A). When the interaction of A, added after S1, 
and a drug B added 5 min before Sn, was studied, the “appropriate control” was a group in 
which A alone was used. 
Results are expressed as mean±s.e.m. and n denotes the number of tissue preparations. 
Differences between means were compared for significance using the unpaired Student’s t-
test or one-way analysis of variance (ANOVA) followed by post-hoc Dunnet’s multiple-
comparison t-test. A value of P<0.05 was considered to denote statistically significant 
differences. 
 
 
RESULTS  
 
NO induced changes in evoked-tritium release: mesenteric and tail arteries 
 
Electrically-evoked tritium overflow from tissue preparations incubated with [3H]-
noradrenaline has been shown to reflect action potential-evoked neuronal noradrenaline 
release[16] and the drug-induced changes in evoked tritium overflow may be assumed to 
reflect changes in neuronal noradrenaline release, as observed in previous studies.[13, 14]  
In the absence of drugs (except 400 nM desipramine, which was present in the 
superfusion medium, in all experiments, to inhibit the neuronal uptake of noradrenaline), 
the fractional rate of outflow immediately before S1 (b1) was 0.0864±0.0065 min-1 (n=15) 
for intact mesenteric arteries. For tail arteries the fractional rate of outflow immediately 
before S1 (b1) was 0.0984±0.0056 min-1 (n=17) or 0.09660±0.0066 min-1 (n=15) for intact 
and denuded tail arteries, respectively. Tritium overflow elicited by S1 was 1.03±0.09% 
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(n=15) of the mesenteric arteries tritium content. In tail arteries, tritium overflow elicited 
by S1 was 0.28±0.04% (n=17) or 0.38±0.08% (n=15) of total tissue content for intact and 
denuded tail arteries, respectively.  Differences with S1 values (P<0.05) were observed 
between S1 values in mesenteric and tail arteries. Basal outflow and electrically-evoked 
tritium overflow remained constant throughout experiments, with b2/b1 and S2/S1 values 
close to unity. 
The influence exerted by NO on noradrenaline release from vascular sympathetic 
nerve endings was tested using NO donors as well as a NO synthase inhibitor in two 
different vascular beds: mesenteric and tail artery (Figure 1).  
 
 
 
 
 
 
Fig. 1 Effects of NO synthase inhibitor (L-NAME, 100 µM) and NO donors (SNP, 10 µM; 
DEA NONOate, 10 µM) on noradrenaline release from rat mesenteric (black bars) and tail 
(white bars) arteries. Ordinates: S2/S1 values obtained in individual tissues preparations 
corrected from the appropriate S2/S1 control value. Values are mean±s.e.m from 6-20 tissue 
preparations; statistically significant differences (ANOVA followed by Dunnet’s or Student’s 
t-test: *p<0.05 or **p<0.001, from the respective control and #p<0.05 or ##p<0.001, from 
the mesenteric arteries preparations). 
 
Results indicate a clear difference in NO mediated effects in these two vessels: in the tail 
artery NO induce an enhancement in [3H]-noradrenaline release while in mesenteric artery 
the effects observed with DEA NONOate (10 µM) and L-NAME (100 µM) indicate a poor 
Adenosine receptors in vascular sympathetic neurotransmission: the role of endothelium and of nitric oxide-
mediated effects and their relation with hypertension 
102 
 
involvement of NO in sympathetic neurotransmission. SNP (10 µM) was able to reduce 
noradrenaline release, an effect that was not mimicked by the other NO donor DEA 
NONOate. This might be explained has previously described by a possible decomposition of 
SNP by tissues attributable to interaction of its ion with sulfhydryl groups.[17] 
 
 
 
 
Fig. 2 Effects of NO synthase substrate (L-Arginine, 1mM) and NO synthase inhibitor (L-
NAME, 100 µM) and NO donors (SNP, 10 µM; DEA NONOate, 10 µM) on noradrenaline 
release from rat intact (black bars) and denuded (white bars) tail arteries. Ordinates: S2/S1 
values obtained in individual tissues preparations corrected from the appropriate S2/S1 
control value. Values are mean±s.e.m from 6-20 tissue preparations; statistically significant 
differences (ANOVA followed by Dunnet´s or Student’s t test: *p<0.05 or **p<0.001, from 
the respective control and #p<0.05 or ##p<0.001, from the endothelium intact artery 
preparations).  
 
 
Role of tail artery endothelium NO in evoked-tritium release 
 
NO was found to be involved in the enhancement of [3H]-noradrenaline release from 
postganglionic sympathetic nerve endings in rat tail arteries (Fig. 1). In order to investigate 
the source of NO involved in this facilitation, experiments with intact and denuded tail 
arteries were carried out. L-NAME (100 µM) failed to modify [3H]-noradrenaline release in 
denuded tail arteries while in intact arteries it reduces [3H]-noradrenaline release (Fig. 2). 
This effect agrees well with a tonic effect mediated by an NO produced most probably in the 
endothelium. Data obtained with NO donors indicate that the signalling pathway activated 
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by exogenous NO (NO donors mediated effects), ultimately causes a reduction in [3H]-
noradrenaline release in denuded arteries, in opposition to the effects observed in intact 
arteries. Clearly, this indicates that distinct pathways are being influenced by NO from 
different sources.  
 
 
CONCLUSIONS 
 
In rat mesenteric artery, the availability of nitric oxide appears to have a poor or no 
effect on sympathetic transmission. Rather, in tail artery, the results support the occurrence 
of a modulating effect on vascular sympathetic transsynaptic transmission mediated by NO. 
Endothelial NO signalling pathways seem to promote noradrenaline release but there is no 
tonic effect mediated by neuronal NO. Data indicate that the signalling pathway activated 
by exogenous NO, ultimately causes a reduction in noradrenaline release in denuded tail 
arteries, in opposition to the effects observed in intact tail arteries. Endogenous NO, 
produced most probably in the endothelium, in turn, mediate an enhancement of 
noradrenaline release. These indicate that NO from different sources can induce opposite 
effects probably through activation/influence of distinct pathways. 
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ABSTRACT 
 
Endothelium is widely recognized as an important regulator of blood vessel tone via 
release of various endothelium-derived endogenous substances, such as nitric oxide (NO).  
The aim of the present study was to clarify the modulatory role exerted by endogenous NO 
(generated by eNOS and nNOS) in sympathetic neurotransmission and to characterize the 
distribution profile of enzyme isoforms involved in NO generation, eNOS and nNOS.  
The role of NO in sympathetic neurotransmission was studied using electrically-
evoked [3H]-noradrenaline release experiments. Localization of NOS isoform in adventitia 
of mesenteric arteries was investigated by Laser Scanning Confocal Microscopy. 
NO donors reduced noradrenaline release in mesenteric arteries while, in tail 
arteries, NO donors caused opposite effects. In mesenteric arteries, L-NAME was devoid of 
effect while both Nω-Propyl-L-arginine hydrochloride, a nNOS inhibitor, and L-NIO 
dihydrochloride, eNOS inhibitor, increased noradrenaline release. In tail arteries, L-NAME 
and L-NIO dihydrochloride reduced noradrenaline release whereas nNOS inhibitor, failed 
to change neurotransmistter release.  Immunohistochemistry revealed that nNOS was 
present in Schwann cells but also in other type of cells in the adventitia of mesenteric and 
tail arteries.  It further showed lower amounts of nNOS in tail arteries comparatively to 
values observed in mesenteric arteries. 
In conclusion, the NO modulatory role on sympathetic neurotransmission differs in 
the mesenteric and tail arteries depending on the NOS isoform, eNOS and/or nNOS, 
involved in its production. Furthermore, nNOS locatization may also be crucial to this effect, 
since nNOS present in Schawnn cells seem to be the main source of NO to perivascular 
sympathetic nerves. 
 
Keywords: NO; sympathetic neurotransmission; nNOS; Schwann cells   
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INTRODUCTION 
 
Endothelium is widely recognized as an important regulator of blood vessel tone via 
release of various endothelium-derived endogenous substances[1, 2] with vasoconstriction 
and/or vasodilation properties.[3, 4] One of such substances is nitric oxide (NO). NO 
contributes to maintain vascular homeostasis by modulating the vascular dilator tone and 
regulating local cell growth. NO is not a locally-acting messenger and the spatial distribution 
of NO in tissue is large. Indeed, since NO is uncharged and highly soluble in hydrophobic 
environments, it can diffuse freely across biological membranes and signal many cell sites 
from its site of generation.[5] Therefore, NO can modify vascular smooth muscle tone 
directly, acting on smooth muscle cells, or indirectly, by altering sympathetic 
neurotransmission.[6-9] Indeed, NO is considered a physiological modulator of 
sympathetic neurotransmission by deactivating noradrenaline in the neurovascular 
junction.[10-14] 
Several studies have suggested that endothelial dysfunction due to decreased nitric 
oxide (NO) production and/or destruction by reactive oxygen species (ROS) contributes to 
hypertension, increasing peripheral vascular resistance.[4, 15-21]. Alterations in NO 
modulation in sympathetic neurotransmission have also been implicated in 
hypertension.[22] NO production occurs via NO synthases (NOS) activation: NOS 
(endothelial NOS, eNOS, and neuronal NOS, nNOS), may generate small amounts of NO 
(picomolar levels) and contribute to homeostasis.[23-25]. 
Recently it has been reported that eNOS expression is paradoxically increased rather 
than decreased in endothelial dysfunction[26-30] and eNOS can lead to the production of 
superoxide rather than NO.[31-36] Moreover, studies concerning NO and its role in 
endothelial regulation of vasomotor tone[37] revealed that endothelial cells may be 
dynamically involved in the vascular response to receptor stimulation, namely α- or β-
adrenoceptors[38] and adenosine receptors.[39-41]. However, the role of nNOS inhibition 
on cardiovascular system is still unclear. Some studies indicated that the inhibition of nNOS 
does not significantly affect blood pressure of both normotensive[42-46] and spontaneously 
hypertensive rats[47] while others have reported that modulation of the L-Arg/NO system 
may be used in therapeutics of hypertension, regulating  NO production.[35, 48, 49] 
The aim of the present study was to clarify the modulatory role exerted by 
endogenous NO (generated by eNOS and nNOS) in sympathetic neurotransmission and to 
characterize the distribution profile of enzyme isoforms involved in NO generation, eNOS 
and nNOS, in the adventitia layer of two arteries, mesenteric and caudal, arteries currently 
used as models to study neurotransmission. 
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MATERIALS AND METHODS 
 
Animals 
 
Adult male WKY (12 weeks old, 270-350 g; Charles River, Barcelona, Spain) were 
used. Handling and care of animals were conducted according to the European guidelines 
(Directive 2010/63/EU) on the protection of animals used for scientific purposes in 
agreement with the NIH guidelines. Two animals per experiment were used. Seven tissue 
segments (5 to 9 mg) were obtained from each tail artery and four tissue segments (4-7 mg) 
were obtained from each mesenteric artery. Briefly, tail arteries were dissected and, for 
experiments with denuded preparations, endothelium was mechanically removed with a 
thin stainless steel wire 
 
 
Chemicals 
 
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 
41.3 Ci/mmol, was from DuPont NEN (I.L.C., Lisboa, Portugal); desipramine 
hydrochloride, (S)-2-Amino-5-guanidinopentanoic acid (L-Arginine), Sodium 
nitroprusside (SNP), Diethylamine NONOate diethylammonium salt (DEA-NONOate), 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME), Nω-Propyl-L-arginine 
hydrochloride and L-NIO dihydrochloride were purchased from Sigma-Aldrich (Sintra, 
Portugal). The following antibodies used: mouse monoclonal anti-NOS1 (sc-5302), were 
purchased from Santa Cruz Biotechnology, Inc., CA, USA; rabbit GFAP polyclonal antibody 
(18-0063) was purchased from Invitrogen, Life Technologies, SA, Madrid, Spain). The 
following fluorescent probes were used: Alexa Fluor® 488 goat anti-mouse IgG (H+L) 
antibody, highly cross-adsorbed and Alexa Fluor® 647 goat anti-rabbit IgG (H+L) 
antibody, highly cross-adsorbed (Molecular Probes®) secondary fluorescent antibodies 
(Invitrogen, Life Technologies, SA, Madrid, Spain); vectashield mounting medium with 
DAPI (Vector Laboratories, UK). Stock solutions were made up in dimethylsulphoxide 
(DMSO: 0.01% v/v, final concentration) or distilled water and diluted in superfusion 
medium immediately before use. DMSO was added to the superfusion medium (final 
concentration 0.01%), in parallel control experiments. 
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[3H]-Noradrenaline release experiments 
 
Evaluation of [3H]-noradrenaline release experiments was carried out as previously 
described.[50-54] Arteries were pre-incubated in 2 ml Krebs-Henseleit solution containing 
0.1 µmol/L [3H]-noradrenaline (for 60 min at 37ºC) and transferred into superfusion 
chambers, superfused with [3H]-noradrenaline-free medium (1 ml min-1; constant rate: 
Krebs-Henseleit solution with desipramine 400 nmol/L to inhibit noradrenaline’s neuronal 
uptake). Up to three periods of electrical stimulation (5 Hz, 100 pulses, 1 ms, 50 mA; Hugo 
Sachs Elektronik, March-Hugstetten, Germany): two stimulation periods (S1 and S2) were 
applied with 30 min intervals, t=90 min and t=120 min, respectively. The superfusate was 
collected each 5 min period from 85 min of superfusion onwards. At the end of the 
experiments (t=130 min), tritium was measured in superfusate samples and solubilized 
arteries (sonicated 1h with 2.5 ml perchloric acid (0.2 mol/L)) by liquid scintillation 
spectrometry (LS 6500, Beckman Instruments, Fullerton, USA) after adding 6 ml of a 
scintillation mixture (OptiPhase ‘Hisafe’ 3, PerkinElmer, I.L.C., Lisboa, Portugal) to each 
sample. 
Tissue labelling with [3H]-noradrenaline and evaluation of electrically-evoked 
tritium overflow changes was performed as previously described.[53, 54] Effects of NOS 
inhibitors and donors, in tail and mesenteric arteries, were studied. 
 
 
Laser scanning confocal microscopy (LSCM) experiments 
 
Immunohistochemistry procedures were as described previously.[54] Four tissue 
preparations were obtained from each artery and immediately placed in cold phosphate 
buffer solution (PBS; in g/L): NaCl 8.0, Na2HPO4.2H2O 0.77, KCl 0.20, KH2PO4 0.19 (pH 
7.2). Each preparation was longitudinally opened and fixed (paraformaldehyde 4% PBS; 50 
min; room temperature, RT). After two 15 min PBS washing cycles, artery segments were 
incubated with primary antibodies raised against nNOS, an mouse monoclonal anti-NOS1 
(1:200 dilution, overnight, 4ºC) or mouse monoclonal anti-glial fribrilary acidic protein 
(GFAP, 1:200 dilution, overnight, 4ºC). Thereafter, tissues were incubated with Alexa 647 
anti-rabbit and Alexa 488 anti-mouse fluorescent secondary antibodies (1:1000 dilution, 1 
h, RT). Negative controls were performed by omitting primary antibodies. After two PBS 
washing cycles, tissue preparations were mounted with antifading agent (vectashield 
mounting medium with DAPI, Vector Laboratories, UK), with the adventitial side facing up. 
Preparations were visualized with a Leica SP5 LSCM system (Leica Microsystems, 
Germany) fitted with an inverted microscope (x63 oil immersion lens). Stacks of 1-µm-thick 
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serial optical images were captured from the entire adventitial layer, which was identified 
by the shape and orientation of the nuclei. Image acquisition was performed always under 
the same laser power, brightness and contrast conditions. Adventitia was scanned along 
each mesenteric and tail arteries and the resulting images were reconstructed separately for 
each wavelength.  
 
 
Data Analysis 
 
Measurement of drug effects on electrically-evoked tritium overflow. 
 
Electrically-evoked tritium overflow from artery segments incubated with [3H]-
noradrenaline has been shown to reflect action potential-evoked neuronal noradrenaline 
release and drug-induced changes in evoked tritium overflow are assumed to reflect changes 
in neuronal noradrenaline release. Effects of drugs added after S1 on electrically-evoked 
tritium overflow were evaluated as ratios of the overflow elicited by S2 and the overflow 
elicited by S1 (S2/S1). S2/S1 ratios obtained in individual experiments in which a test 
compound A was added after S1 were calculated as a percentage of the respective mean ratio 
in the appropriate control group (solvent instead of A).  
 
Laser Scanning Confocal Microscopy images quantification 
 
Quantitative analysis of confocal z-stacks images was performed using image 
analysis software (PAQI, CEMUP, OPorto, Portugal). Briefly, a sequential routine was 
designed and developed to analyse each fluorescent signal used. PAQI software measured 
the surface area and strength of the receptors, the surface area and strength of the Schwann 
cells and determined the surface area of attachment of the receptors on the Schwann cells. 
 
Statistics 
 
Results are expressed as mean±s.e.m. and n denotes the number of tissue 
preparations. Differences of means were compared for significance using one- or two-way 
ANOVA followed by post-hoc Holm-Sidak’s multicomparisons. A P value lower than 0.05 
was considered to denote statistically significant differences. 
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RESULTS 
 
The fractional rate of basal tritium outflow (b1) and electrically-evoked tritium 
overflow (S1) of mesenteric and tail arteries are shown in Table 1 and Figure 1. Electrically-
evoked tritium overflow (S1) is similar in mesenteric and tail arteries but is more 
pronounced in denuded arteries evidencing, clearly, the importance of endothelium in 
sympathetic neurotransmission. Moreover, in mesenteric denuded-arteries S1 value is even 
more pronounced (almost the double) than that exhibited by tail arteries. Basal outflow and 
electrically-evoked tritium overflow remained constant throughout the experiments, with 
bn/b1 and Sn/S1 values of control samples close to unity (data not shown). 
 
 
 
Table 1. Basal tritium outflow (b1), electrically-evoked tritium overflow (S1) 
and S2/S1 ratios from mesenteric and caudal arteries 
            Basal Outflow (b1)     Evoked Overflow (S1) S2/S1        n 
(fractional rate of    (% of tissue tritium 
outflow; min-1)  content) 
Mesenteric artery 0.070±0.008      0.229±0.037 0.9801±0.048    15 
Caudal artery              0.075±0.003       0.185±0.015 1.0275±0.081     25 
Tissue preparations of mesenteric and caudal arteries were pre-incubated with [3H]-noradrenaline 
for 40 min. After pre-incubation with [3H]-noradrenaline, tissues were superfused with [3H]-
noradrenaline free medium containing desipramine (400 nM). Tissues were stimulated twice at 30-
min intervals (S1-S2; 100 pulses, 5 Hz, 1 ms, 50 mA): b1 refers to the 5-min period immediately before 
S1. The electrically-evoked tritium overflow was calculated by subtracting the estimated basal outflow 
from total outflow observed during and in the 25-min period subsequent to S1 and expressed as a 
percentage of the tissue tritium content at the onset of stimulation. Values presented are 
means±SEM and n denotes the number of tissue preparations. Differences of means were compared 
for significance using Student´s t test): *P<0.05 
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Figure 1. Time course of tritium outflow from intact (filled circles) and denuded (open circles) tail 
artery segments, and from intact (filled triangles) and denuded (open triangles) mesenteric artery 
segments, taken from a typical experiment. After pre-incubation with [3H]-noradrenaline, tissues 
were superfused with [3H]-noradrenaline free medium containing desipramine (400 nM). Tritium 
outflow (ordinates) is expressed as a percentage of the total radioactivity present in the tissue at the 
beginning of the collection period and was measured in samples collected every 5 min. Artery 
segments were stimulated twice(S1, S2) by 100 pulses/5 Hz, 1 ms, 50 mA. Each line represents the 
outflow of tritium from a single superfusion chamber. 
 
 
 
Nitric oxide in sympathetic neurotransmission in mesenteric and tail artery  
 
The nitric oxide donor DEA/NONOate (10 µM) reduced the electrically-evoked 
tritium overflow from mesenteric arteries. Similar results were obtained in the presence of 
another NO donor, SNP (10 µM; Fig 2A). In contrast, in tail arteries both NO donors induced 
an increase of electrically-evoked tritium overflow, as depicted in Fig 2A. L-arginine, a NOS 
substrate, facilitated tritium release both in mesenteric and tail arteries.  
In a set of experiments, endothelium denuded mesenteric and tail arteries were used 
to determine the role of NO in sympathetic postganglionic terminals. In these conditions, 
the two NO donors, DEA/NONOate and SNP, did not affect tritium overflow in mesenteric 
arteries but inhibited tritium overflow in tail arteries (Fig 2B). L-arginine induced a 
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facilitation in tritium release in mesenteric artery while in tail artery, it did not change 
electrically-evoked tritium release (Fig 2B) suggesting the inactivation, or absence, of NOS 
signaling machinery in tail artery. In addition, L-arginine induced facilitation was more 
pronounced in endothelium denuded compared to that observed in intact mesenteric 
arteries (P<0.05) indicating a putative occurrence of different NOS-signalling events or the 
involvement of different NOS subtypes.  
 
 
 
 
 
Figure 2. Influence of nitric oxide donors on the modulation of electrically-evoked tritium overflow 
in intact (panel A) and denuded (panel B) tail and mesenteric arteries: interaction with L-Arginine 
(1 mM, a substrate for NOS) and nitric oxide donors, SNP (10 µM) and DEA-NONOate (10 µM). 
Arteries were electrically stimulated (S1-S2: 100 pulses, 5 Hz, 1 ms, 50 mA). Drugs were added 
immediately after S1 and kept until the end of the experiment. Ordinates: S2/S1 values obtained in 
individual tissue preparations, expressed as a percentage of the appropriate S2/S1 control value. 
Values are mean±s.e.m. from 7-24 tissue segments. Significant differences from the appropriate 
control: *P<0.05; **P<0.001 (two-way ANOVA followed by post-hoc Holm-Sidak’s 
multicomparisons t-test). 
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Endogenous nitric oxide production in mesenteric and tail arteries: role of 
eNOS and nNOS  
 
L-NAME, described as a non-selective NOS inhibitor, L-NIO dihydrochloride, 
considered a more selective eNOS inhibitor, and Nω-Propyl-L-arginine hydrochloride, a 
more selective nNOS inhibitor, were used to challenge this later possibility (Fig.3). 
In tail artery, L-NAME and L-NIO dihydrochloride reduced electrically-evoked 
tritium overflow, an effect compatible with the facilitatory role of NO described above in 
this artery whereas nNOS inhibitor, failed to change tritium release (Fig 3). In endothelium 
denuded tail arteries nNOS and eNOS inhbitors also failed to modify tritium release 
(98.90±6.81%; n=9 and 109.56±13.02%; n=4, respectively; values corrected from S2/S1 of 
the appropriate control samples).  
 
 
 
Figure 3. Influence of nitric oxide inhibitors on the modulation of electrically-evoked tritium 
overflow in tail and mesenteric arteries: interaction with nitric oxide inhibitors L-NAME (100 µM, a 
non-selective nNOS inhibitor), Nω-Propyl-L-arginine hydrochloride (100 nM, a selective nNOS 
inhibitor) and L-NIO dihydrochloride (500 nM, a selective eNOS inhibitor). Arteries were electrically 
stimulated (S1-S2: 100 pulses, 5 Hz, 1 ms, 50 mA). Drugs were added immediately after S1 and kept 
until the end of the experiment. Ordinates: S2/S1 values obtained in individual tissue preparations, 
expressed as a percentage of the appropriate S2/S1 control value. Values are mean±s.e.m. from 7-24 
tissue segments. Significant differences from the appropriate control: *P<0.05; **P<0.001 (two-way 
ANOVA followed by post-hoc Holm-Sidak’s multicomparisons t-test). 
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When we evaluate the effects elicited by these NOS inhibitors on the evoked tritium 
release in the mesenteric arteries we detected a different profile: L-NAME was devoid of 
effect while Nω-Propyl-L-arginine hydrochloride, a nNOS inhibitor, was able to increase 
tritium release up to 49% and L-NIO dihydrochloride, eNOS inhibitor, up to 45%.   
Results are suggestive of different NOS subtypes producing NO in locations where 
the subsequent signaling cascade drives to different neuromodulatory roles or, 
alternatively, the amount of NO produced may differ and, consequently, differently 
influence neurotransmission.  
 
 
Characterization of nNOS distribution in the adventitia of mesenteric and 
tail arteries 
 
In mesenteric and tail arteries immunoreactivity for nNOS (anti-NOS1-
immunoreactive) was found in the adventitia layer, but the relative amount of nNOS present 
in tail arteries is much lower (~27%) than that exhibited in mesenteric arteries (Figure 4). 
Previously we have showed that sympathetic nerves are surrounded by Schwann cells (anti-
GFAP-immunoreactive) and, therefore, we tested the possibility that nNOS could be 
expressed in these cells since they have a trophic role to sympathetic neurons:  NOS1 and 
GFAP staining overlay might indicate that they could be located on the same cellular 
structure.  
Figure 4C shows that NOS1 and GFAP overlaid immunoreactivities markedly 
decrease in tail as compared with mesenteric arteries when data was normalized by the total 
GFAP immunoreactivity: 50% of Schwann cells exhibit NOS1 immunoreactivity in 
mesenteric arteries versus the 4% observed in tail arteries. Similar results were also 
observed in Figure 4D (upon normalization of NOS1-GFAP overlay with the total NOS1 
immunostaining). NOS1 immunoreactivity was also observed in cells other than Schwann 
cells in both mesenteric and tail artery images: 62.5% in mesenteric and 88% in tail artery 
images (Figure 4 A e D).  
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Figure 4. nNOS in Schwann cells in the adventitia of tail and mesenteric arteries. Confocal 
immunofluorescence representative images of adventitial tail and mesenteric arteries (A) 
immunostained for nNOS (a primary mouse monoclonal anti-NOS1 and a species specific secondary 
Alexa 488 antibody: green), or GFAP (a primary rabbit anti-GFAP polyclonal antibody and a species 
specific secondary Alexa 647 antibody: magenta) and DAPI (nuclear fluorescence stain, blue) were 
obtained using LSCM (all images are reconstructions from 11-28 serial optical sections). (B) Relative 
means of nNOS, GFAP and nNOS-GFAP overlay expressed as percentage of mesenteric artery values. 
(C) Mean percentage of overlay rate with GFAP (D) and mean percentage of overlay rate with nNOS 
are depicted. Values are mean±s.e.m.; 3-4 animals. Significant differences from mesenteric artery: 
#P<0.05, ## P<0.001. Scale bar = 20 µm. 
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DISCUSSION 
 
In the present study we have demonstrated that neuromodulation exerted by NO in 
vascular sympathetic postganglionic nerves is largely dependent on: i) the NOS isoform that 
generates it, probably due to ii) the different distribution of NOS isoforms, eNOS and nNOS, 
or to iii) differences in the relative amount of nNOS isoform in the two arteries. 
In this study we used two different arteries, mesenteric and tail, that have been used 
as model for the study of the neuromodulatory role of many substances in the 
vasculature.[6, 8, 9, 55-57] In mesenteric arteries NO-mediated effects in 
neurotransmission has been largely studied.[12] Our data with selective isoform NOS 
inhibitors, in intact mesenteric arteries, showed facilitation of noradrenaline release of 
similar magnitude, an effect that correlates well with previous studies in rat[8, 10-12] and 
rabbit[58] mesenteric arteries describing NO as a mediator able to reduce noradrenaline 
release. However, the non-selective NOS inhibitor, L-NAME, which inhibits both isoforms 
from producing NO, failed to modify noradrenaline release. These results suggest that in 
mesenteric arteries both nNOS and eNOS contribute to NO production that, ultimately, 
leads to a decrease in noradrenaline release. However, NO donors failed to modify 
noradrenaline release, in our experimental conditions, in both intact and denuded arteries, 
which may indicate that endogenous NO neuromodulation have achieved its maximum 
effect. Curiously, the non-selective substrate for NOS, L-arginine, facilitated noradrenaline 
release, in intact and denuded mesenteric arteries, contrary to what was observed in tail 
arteries where endothelium removal eliminated the facilitatory effect. This data indicate 
that in mesenteric arteries, NOS seem to produce other substance than NO, active in 
changing neurotransmission as well. L-citrulline could be such mediator since other authors 
have previously described its involvement as a neuromodulator in rat motor nerve 
endings.[59, 60] 
In intact tail arteries, however, we found a different neuromodulatory role of NO in 
neurovascular junction since increase in NO amount, via addition of NO donors, increased 
noradrenaline levels. Curiously, in denuded tail arteries, and by opposition, NO increase 
inhibited noradrenaline release. This may indicate that different signalling mechanisms 
would be triggered in the presence or in the absence of endothelium. Information gathered 
recently may explain these data through the occurrence of nitrite production and nitrite-
mediated effects.[61] Indeed, the nitrite reductase activity was described to be located in the 
oxygenase domain of eNOS[62]  and that inhibition with L-NAME would attenuate the 
production of NO from nitrite.[63] eNOS would have a center role in this type of effect and 
its activity, either as nitrite reductase or as NOS synthase, in intact tissues would explain 
the facilitatory effects observed. In denuded arteries, the lack of, or diminished amount, of 
Adenosine receptors in vascular sympathetic neurotransmission: the role of endothelium and of nitric oxide-
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eNOS would explain the opposite results. Moreover, this possibility agrees well with the 
results obtained using several NOS inhibitors. In intact tissues, both the selective eNOS 
inhibitor, L-NIO dihydrochloride, as well as the non-selective NOS inhibitor, L-NAME, 
reduced noradrenaline release, whereas in denuded arteries they did not change 
noradrenaline release. Furthermore, the nNOS inhibitor, Nω-Propyl-L-arginine 
hydrochloride, failed to modify noradrenaline release both in intact and denuded tail 
arteries suggesting a crucial role for eNOS in the increase of noradrenaline release detected. 
Confocal microscopy studies showed the presence of nNOS isoform in the adventitia 
layer of both mesenteric and tail arteries, confirming previous reports.[64] Confocal 
microscopy data agrees well with the absence of nNOS activity found in the tail artery since 
a considerable lower amount (a reduction of 27%) of this isoform was detected in the 
adventitia of tail comparatively to mesenteric arteries. Our data also show, for the first time, 
that nNOS is distributed in two main locations: one expressed in Schwann cells and another, 
more abundant in other cells:  about 63% and 88% in the adventitia of mesenteric and tail 
arteries, respectively. Therefore, it is fair to speculate that nNOS, expressed in Schwann 
cells, might be producing NO that can be causing the inhibition of noradrenaline release 
from sympathetic nerves.  Our findings are in agreement with this possibility since the 
relative amount of nNOS expressed in Schwann cells in the two arteries are markedly 
different: 50% in mesenteric vs 4% in tail arteries. These data also correlates with the 
functional results obtained that showed a lack of neuromodulatory role of nNOS in tail 
arteries whereas, in mesenteric arteries, nNOS contributed to reduce by half noradrenaline 
release. 
Another important finding concerns the changes in sympathetic neurotransmission 
observed in denuded arteries suggesting that when arterial endothelium integrity is 
somehow compromised the levels released of noradrenaline in neurovascular junction 
increase, contributing to vasoconstriction.  Indeed, in addition to NO, as explained above, 
the absence of other endothelium derived substances such as adenosine, endothelin-1, etc 
might be contributing to the increase of noradrenaline release observed. 
In summary, the present results suggest that the NO modulatory role on sympathetic 
neurotransmission differs in the mesenteric and tail arteries depending on the NOS isoform, 
eNOS and/or nNOS, involved in its production.  Moreover nNOS location may also be 
crucial to this effect, since nNOS present in Schawnn cells seem to be the main source of NO 
to perivascular sympathetic nerves. 
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DISCUSSION 
 
Evidence has highlighted the role of vascular sympathetic neurotransmission in the 
regulation of vascular tonus.[1-3]  Indeed, modification of adenosine receptor-mediated 
effects has been recently suggested to contribute to hypertension pathoetiology.[4-7] 
Combined application of different methodologies provided complementary information 
allowing a better understanding of how sympathetic neurotransmission is affected in 
pathological conditions such as hypertension and endothelium dysfunction. Electrically-
evoked [3H]-noradrenaline release experiments allow to analyze the effects caused by 
endogenous adenosine and nitric oxide on the amount of noradrenaline released from 
sympathetic nerves of the vessels, and how their action could be changed in the hypertensive 
state. The mechanisms by which these mediators could be altering neurotransmitters 
release and be influenced by endothelial dysfunction were also evaluated. Measurement of 
the amounts of ATP and adenosine released in these experiments were also carried out 
clarifying their role as neurotransmitter or neuromediator, respectively. 
Immunohistochemical studies revealed how distribution (redistribution) of both 
membrane proteins, such as adenosine receptors, or enzymes could occur in pathological 
conditions influencing, therefore, the ability of these proteins to be activated. 
The work carried out in this thesis allowed to identify and understand some of the 
changes in vessel physiology during hypertension, particularly those concerning the levels 
of neurotransmitter release and the dynamics of adenosinergic system. The latter is related 
with the amounts of nucleosides and/or nucleotides, which depend both on nucleotide 
metabolism and nucleoside transporter activity, and individual adenosine receptor subtype 
activation. Other important mediator in vessels is NO and its effects were found to be largely 
dependent on the isoform that produced it, nNOS or eNOS. These isoforms presence and 
distribution can condition the amount of NO available and, therefore, NO-mediated effects.  
Two different arteries, mesenteric and tail arteries, which have been extensively used as 
models to study the neuromodulatory role of many substances in the vasculature, were 
used. 
In hypertensive conditions, sympathetic neurotransmission was found to be altered 
occurring an increase in the release of both co-transmitters, noradrenaline and ATP.[8] The 
increase in the concentration of these neurotransmitters in the synaptic cleft may lead, 
ultimately, to an increase in vascular reactivity and vasoconstriction by activation of α2 
adrenoceptors (by noradrenaline) or P2 receptors (by ATP). Moreover, we showed that the 
increased levels of noradrenaline release found in hypertensive state can be justified by i) 
the absence of tonic inhibitory adenosine A1 receptor-mediated effects which, in 
normotensive conditions inhibited sympathetic transmission, ii) the  redistribution of 
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adenosine A1 receptors to Schwann cells, which may hinder adenosine A1 receptor 
activation,  iii) the preserved facilitatory adenosine A2A receptor-mediated effects, a via only 
activated with higher adenosine amounts than those needed to activate adenosine A1 
receptors, iii) an enhancement of adenosine levels as a consequence of the metabolism of 
the higher levels of electrically-evoked ATP released in the hypertensive state and iv) the 
fact that NO availability may be compromised since eNOS seem to be inactive. 
In normotensive mesenteric and tail arteries, tonic adenosine A1 receptor mediated 
effect inhibited noradrenaline released, an effect mediated predominantly by adenosine 
originated from metabolism of released adenine nucleotides.  This indicates that, under 
basal conditions, inhibitory adenosine A1 receptors operate to restrain noradrenaline 
release, as a consequence of adenosine accumulation from hydrolysis of ATP released from 
neighbouring cells. Moreover, the amount of ATP released from sympathetic nerves was 
higher in SHR than in WKY mesenteric arteries which may lead to P2 receptors activation, 
revealing ATP as an important vasoconstrictor in hypertensive arteries, a role recently 
described by Goonetilleke and co-workers (2013).[8]  
Neurotransmitter release modulation ascribed to extracellular adenosine 
accumulation depends both on its formation and on cellular uptake and deamination. 
Adenosine uptake seems to be the dominant adenosine inactivation pathway in arteries. 
Nucleoside transporter inhibition can increase extracellular adenosine to levels high enough 
to activate adenosine A2A receptors, while in its absence the amount of adenosine is only 
sufficient to activate adenosine A1 receptors, which can be explained by the difference in 
their Kd´s.[9] Since adenosine A2A receptors require concentrations two-fold higher than 
those needed to activate adenosine A1 receptors, endogenous adenosine availability is 
crucial to discriminate the subtype of adenosine receptor that is activated. In conditions that 
favour extracellular adenosine accumulation, this nucleoside may also reach concentrations 
high enough to activate adenosine A2A receptors, leading to the increase of noradrenaline 
release and, consequently, of sympathetic activity. 
Laser scanning confocal microscopy data confirmed previous reports of a 
sympathetic hyperinnervation in hypertensive arteries. However, increases in the number 
and thickness of sympathetic nerve fibres observed in SHR arteries was not accompanied 
by a correspondent enhancement of adenosine A1 and/or A2A receptors overlaying these 
neurons. These lower adenosine A1 receptors amount can explain, at least in part, the lack 
of adenosine inhibitory tone regulating noradrenaline release from stimulated SHR 
arteries, leading to higher extracellular noradrenaline levels.  
Adenosine A1 and A2A receptors are present in other cells than sympathetic neurons. 
These cells were identified as being glial cells, more specifically, Schwann cells, which have 
a trophic role for nerve cells in the adventitial layer of these arteries. In hypertensive 
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arteries, an increase amount of receptors can be observed in non-neuronal cells suggesting 
a neuron-to-glia redistribution of adenosine A1 receptors. Changes in the localization of 
adenosine receptors and the increased amount of extracellular adenosine observed in SHR 
arteries suggest that receptor desensitization may be the main reason for adenosine 
receptor activity impairment observed in hypertensive arteries. These results can help to 
clarify current unknown aspects of the complex interplay between receptor expression and 
the role of adenosine. 
It is clear from the literature that, in hypertension, endothelium function is 
compromised.[10-12]  It is also accepted that endothelium derived substances alter vascular 
reactivity.[13, 14] To evaluate if endothelium could also alter vascular sympathetic 
neurotransmission, arteries were denuded (mechanical or chemically). In these conditions 
an increase in noradrenaline release from vascular sympathetic nerves was found. In SHR 
arteries (vessels that exhibit endothelial dysfunction)[15-18]  this increase of noradrenaline 
release is also occurring. In denuded arteries, endogenous adenosine tonically activates 
adenosine A2A receptors leading to a marked increase in noradrenaline release 
comparatively to the activity observed in intact arteries, an effect also observed, with similar 
magnitude, in SHR arteries. Moreover, an additional contribution to the increased 
sympathetic activity observed in these tissues (both denuded and SHR arteries) can be 
ascribed to the absence of inhibitory A1 receptor-mediated effects. Therefore, the 
sympathetic activity impairment observed in arteries exhibiting some degree of 
endothelium dysfunction can be ascribed to alterations in the dynamics of the adenosinergic 
system.  
Adenosine receptors, nucleoside transporters and adenosine availability are 
accepted to be key effectors in the dynamics of adenosinergic system and any change in one 
of these items may cause profound impact in the function of the others. In denuded arteries, 
a facilitation of noradrenaline release was observed when adenosine availability was 
increased. This effect may be due to the absence of nucleoside uptake to endothelial cells 
that seems to be the main mechanism that regulates adenosine extracellular levels. Thus, 
when endothelium is somehow compromised this transport seems to be deregulated 
causing accumulation of extracellular adenosine. Indeed, it seems that endothelium 
dysfunction causes an increase in noradrenaline released levels, contributing to 
vasoconstriction, an additional aggravating factor to hypertension.  
Our results ruled out the involvement of endothelium-derived substances (ROS and 
prostaglandins) in mechanisms leading to altered neuromodulation, whereas adenosine-
mediated neuromodulatory mechanisms were found to be impaired by endothelium 
injury/dysfunction. Evidence in the literature indicated that NO-induced vasodilation may 
be compromised in hypertension.[13, 18-23] NO mediated effects in vascular sympathetic 
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neuromodulation were found to be dependent on the NOS isoform that generates it, 
probably due to the different distribution of NOS isoforms, eNOS and nNOS in arteries, or 
to differences in the relative amount of nNOS isoform in the two arteries studied. 
In mesenteric arteries, selective isoform NOS (nNOS and eNOS) inhibitors caused a 
facilitation of noradrenaline release of similar magnitude. Therefore, both nNOS and eNOS 
contribute to NO production reducing noradrenaline release. However, in the presence of 
exogenous L-arginine a facilitation of noradrenaline release was observed suggesting the 
activation of alternative pathways: NOS seem to produce other substance than NO, which 
can be L-citrulline, an active neuromediator.[24, 25] 
In intact tail arteries we found a different neuromodulatory role of NO since it 
increased neurovascular sympathetic activity, contrary to what is described to occur in most 
arteries.[26] Curiously, and by opposition, in denuded tail arteries, NO inhibited 
noradrenaline release. Findings indicate that different signalling mechanisms would be 
triggered in the presence or in the absence of endothelium, probably due to the occurrence 
of nitrite and nitrite-mediated effects.[27] In the oxygenase domain of eNOS, a nitrite 
reductase activity was described[28] and its inhibition would attenuate the NO production 
from nitrite.[29, 30] Data indicate that eNOS would produce the predominant effect, and 
its activity either as nitrite reductase or as nitric oxide synthase, in intact tissues would 
explain the facilitatory effects observed. In denuded arteries, the lack of, or diminished 
amount of eNOS, observed in our work, would explain the observed opposite results.  
The absence of effects mediated by nNOS in tail arteries revealed this additional 
feature of eNOS, once NO availability was found to be dependent only of eNOS activity. In 
mesenteric arteries, however, nNOS is active and produces enough NO to mask the nitrite 
reductase activity exhibited by eNOS. This possibility is in agreement with the results 
obtained using several NOS inhibitors and also with laser scanning confocal microscopy 
experiments. In intact tail arteries, the selective eNOS inhibitor reduced noradrenaline 
release, whereas in denuded tail arteries it failed to modify noradrenaline release. 
Furthermore, the nNOS inhibitor did not modify noradrenaline release both in intact and 
denuded tail arteries, suggesting a crucial role for eNOS in the increase of noradrenaline 
release detected.  
Distribution of nNOS isoform in the adventitia layer of both mesenteric and tail 
arteries revealed the existence of considerable lower amounts of this isoform in tail arteries 
compared to mesenteric arteries. Other important aspect, that should be highlighted, 
concerns the expression of nNOS in Schwann cells in the adventitia layer of mesenteric and 
tail arteries. The hypothesis that nNOS, expressed in Schwann cells, might produce NO that 
causes noradrenaline release inhibition from sympathetic nerves can be raised. Our findings 
are in agreement with this possibility: the relative amount of nNOS expressed in Schwann 
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cells in the two arteries is markedly different. Additionally, the functional results obtained 
also support this hypothesis since they showed a lack of neuromodulatory role of nNOS in 
tail arteries whereas, in mesenteric arteries, nNOS contributed to reduce, by half, 
noradrenaline release.  
 
 
 
CONCLUSIONS 
 
Results from this work clarified some aspects related with vascular sympathetic 
neurotransmission, particularly when endothelium dysfunction and/or hypertension is 
present. Our experimental approach allowed to clarify the role of endogenous adenosine 
and nitric oxide in the modulation of sympathetic neurotransmission and verified that they 
were impaired in hypertension. Data showed that an increase in the sympathetic activity in 
hypertensive arteries may be partially due to a higher content in ATP release from 
sympathetic postganglionic nerves and the lack of endogenous adenosine inhibitory tonus. 
The latter might be explained by the nerve-to-glial redistribution of inhibitory adenosine A1 
receptors found to occur in hypertensive arteries. These mechanisms would lead to an 
increase in noradrenaline and ATP release from stimulated sympathetic nerves. Taken this 
into account one can predict that, in the synaptic cleft, in addition to the higher levels of 
noradrenaline, increased amounts of ATP are likely to accumulate, both leading to 
subsequent vasoconstriction of vascular smooth muscle cells. Moreover, endogenous 
adenosine neuromodulatory role of sympathetic transmission is significantly impaired in 
mesenteric and tail arteries from hypertensive rats. In SHR mesenteric arteries we failed to 
detect both adenosine A1 and A2A receptor mediated effects. This is occurring despite the 
extracellular levels of both ATP and adenosine being significantly higher in hypertensive 
mesenteric arteries than those measured in normotensive artery superfusates. Additionally, 
using selective adenosine receptor agonists, it was found that the neuromodulatory activity 
of adenosine A1 receptor, but not of adenosine A2A receptors, is significantly impaired in 
hypertensive mesenteric arteries. In this regard, these differences on adenosine 
neuromodulation may be explained by the occurrence of adenosine A1 receptors 
desensitization and redistribution to Schwann cells.  
Our data also allowed to confirm the hypothesis that endothelial dysfunction is 
altering vascular sympathetic neurotransmission contributing to increase vascular tone. In 
mesenteric arteries both nNOS and eNOS contribute equally to NO production conducing 
to a reduction of noradrenaline release. However, in tail arteries, the absence of nNOS 
seems to be conditioning NO levels. Moreover, the fact that eNOS can present nitrite 
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reductase activity may lead to a reduction of NO levels. This can explain the facilitation of 
noradrenaline release observed in tail arteries, where the inhibitory effect of NO is absent 
or reduced in these vessels. 
The presence of nNOS isoform in Schwann cells and the occurrence of redistribution 
of adenosine receptors to Schwann cells in pathological conditions reinforce the importance 
of these cells in the peripheral nervous system.  These findings can help us to understand 
the impact of those alterations in vascular reactivity, contributing to hypertension, renewing 
the interest of purinergic system as a target for novel therapeutic strategies.  
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